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Rett Syndrome (RTT) is an X-linked neurodevelopmental disorder caused mostly by 
disruption of the MECP2 gene. One of the major RTT symptoms is breathing dysfunction. Most 
studies on RTT used male mouse models of the disease though it occurs mostly in females. To be 
able to identify symptomatic female mice we studied how to objectively identify these mice. 
Based on their respiratory phenoytpes, we identified measures that can reliably identify 
symptomatic heterozygous Mecp2 mice. These mice can be treated with high CO2 concentrations 
to improve their respiratory conditions. Similarly, as male models are not an ideal animal model 
for studying RTT, the mutation used to create the most widely used mouse model of RTT is not 
representative of the disease. The Bird mouse model has a deletion of exons 3 and 4 of the gene 
Mecp2 rendering it nonfunctional which rarely occurs in humans. The R168X mutation is one of 
the most common RTT-causing mutations and studies in Bird mice need to be validated using a 
more relevant model. We found that R168X mice have similar respiratory and motor symptoms 
as Bird mice. We also found that locus coeruleus (LC) and mesencephalic trigeminal (Me5) 
neurons which have respiratory and motor functions respectively are also both similarly affected 
by the different gene mutations. Understanding the cellular defects caused by Mecp2 mutations, 
we sought to identify a novel treatment method to alleviate respiratory dysfunction. We 
identified an over-the-counter antitussive that targets brainstem neurons to inhibit autonomic 
functions. The drug Cloperastine (CPS) (30mg/kg, i.p.) decreased the occurrence of apnea counts 
as well as breath frequency variation in Mecp2-null mice. CPS seems to cause this effect by 
reducing cellular excitability by enhancing GABA transmission. This effect was seen in both LC 
and dorsal tegmental nucleus neurons. Our evidence suggests that CPS preferentially blocks 
GIRK channels located on GABAergic synaptic terminals. These results indicate female mouse 
models can be reliably be used to study the mechanisms of Mecp2 dysfunction, clinically 
relevant Mecp2 mutations may coincide with gene knockout studies, and CPS may be a novel 
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1 SPECIFIC AIMS AND HYPOTHESES 
Rett Syndrome (RTT) is a neurodevelopmental disorder seen in approximately 1:10,000 
females. Approximately 95% of cases of RTT are caused by mutations in the gene encoding 
methyl-CpG-binding protein 2 (MECP2). Mouse models of RTT recapitulate many of the 
symptoms seen in human patients, such as breathing abnormalities, motor dysfunction, and 
social disruption. Impairment of the autonomic nervous system controlled by the brainstem is of 
special interest. One such impairment, breathing dysfunction, is also associated with cardiac 
arrhythmias and sudden death [1]. Most studies performed to elucidate the mechanisms of 
breathing impairment in RTT have used male Mecp2-null mouse models. The male mouse 
models with complete gene knockout have several benefits to the studies, such as the 
manifestation of severe RTT-type symptoms, phenotype consistency that is not seen in female 
models due to random X-chromosome inactivation, and early appearance of RTT-type symptoms 
shortening experimental time. However, several questions remain: 1) As RTT mostly affects 
females, how representative are the results obtained from male mouse models? 2) How are the 
RTT phenotypes found in Mecp2 gene knockout compared to natural Mecp2 defects such as the 
R168X gene mutation that occurs in human patients? 3) Because the brainstem plays a critical 
role in RTT symptom development, is it possible that brainstem-targeting respiration-regulatory 
drugs improve these symptoms? Therefore, these thesis studies were designed to address these 
questions. We chose to use a multidisciplinary approach taking advantage of plethysmography, 
electrophysiology, optogenetics, cell culture, and several behavioral assays. I hypothesize that 
there are behavioral and cellular RTT phenotypes that are reproducible, quantifiable, and 
consistent among Mecp2-null, R168X, and female Mecp2+/- mouse models, which can be 
improved by the drug cloperastine acting on brainstem neurons. The objective of these 
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thesis studies is to test this hypothesis. Thus, we designed experiments to address three specific 
aims. 
Specific Aim 1: To identify objective indicators of RTT breathing phenotypes in 
heterozygous Mecp2 mice. 
Experiments were performed in Mecp2+/- mice with several questions to address: Are 
there different populations of Mecp2+/- mice based on their respiratory phenotype? Can these 
populations be objectively separated based on quantifiable measures? What percentage of 
Mecp2+/- mice resemble a WT or Mecp2-/Y phenotype? Does symptom severity progress with 
age? Can exposure to elevated levels of CO2 reduce the severity of breathing abnormalities, as 
seen in Mecp2-/Y mice? These experiments are expected to objectively identify symptomatic 
Mecp2+/- mice based on the breathing phenotype, and provide reliable biomarkers of breathing 
abnormalities. 
Specific Aim 2: To determine behavioral and cellular phenotypes of the missense 
mutation R168X in the Mecp2 gene compared to the effects of the model of whole gene 
deletion.  
Experiments were performed in Mecp2R168X/Y mice with several questions to address: 
How do behavioral phenotypes of Mecp2R168X/Y mice compare to those of Mecp2Bird/Y mice? 
How do the electrophysiological properties of respiratory and motor-related neurons of 
Mecp2R168X/Y differ from those from Mecp2Bird/Y mice? Are the cellular effects of Mecp2 
mutations similar in symptomatic and asymptomatic Mecp2+/- mice? These experiments are 
expected to compare the R168X with the Mecp2-null mouse models with quantitative behavioral 
and cellular data. 
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Specific Aim 3: To test the brainstem-targeting drug cloperastine in the treatment of 
RTT breathing dysfunction and elucidate the cellular mechanisms. 
Experiments were performed in Mecp2-null mice with several questions to address: What 
is the potency for cloperastine (CPS) to inhibit GIRK channels? Can CPS improve breathing 
abnormalities in Mecp2-null mice? What are the cellular mechanisms of CPS’s effects? These 
experiments are expected to provide information on the potency of CPS in GIRK channel 
inhibition, its effectiveness in treating breathing abnormalities in Mecp2-null mice, and the 
underlying cellular mechanisms. 
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2 INTRODUCTION  
2.1 Rett Syndrome 
Rett Syndrome (RTT) is an X-linked neurodevelopmental disorder seen in approximately 1 
in 10,000 females. It is the second leading cause of developmental disability in females. 
Approximately 95% of cases are caused by loss-of-function mutations in the gene methyl-CpG-
binding protein 2 (MECP2). Boys who have MECP2 mutations typically do not survive to birth 
or die shortly after. Girls, however, have an extra copy of the X chromosome, allowing for 
compensation of the defective gene and survival.   
Development for the first 6-18 months after birth is viewed as normal, although some early 
symptoms do manifest [2-4]. Diagnostic criteria for this disease include partial or complete loss 
of spoken language, purposeful hand movement, gait abnormalities, and stereotypic hand 
movements [5, 6]. Other common symptoms include delayed growth, microcephaly, hand 
wringing, breathing abnormalities, abnormal muscle tone, teeth grinding, and cognitive 
impairment. After the initial phase of regression, patients undergo accelerated symptom 
development lasting several months, followed by a plateau phase of symptom progression and 
then a final stage of symptom deterioration, which may last for years [6]. Though lifespan has 
not been well studied, afflicted individuals typically reach adulthood. 
2.1.1 MECP2 gene mutations 
MECP2 disruption in the brain has been considered to be the primary contributor to 
symptom development in RTT. A study has demonstrated that Mecp2 deletion selectively in 
neurons of mice causes phenotypes similar to whole-body knockouts, such as reduced body 
weight and smaller neuronal size [7]. Supporting the finding, another study demonstrated that 
selective knockout of Mecp2 in peripheral tissues avoided the development of typical RTT-type 
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symptoms such as cardiac arrhythmia, respiratory disorder, and motor dysfunction [8]. Further 
supporting the significance of neuronal dysfunction in RTT are studies demonstrating emergence 
of RTT-like phenotypes from selective deletion of Mecp2 in neuronal subpopulations [9, 10].  
Though neuronal dysfunction seems to be a primary driver of RTT development, other cell 
types within the brain seem to contribute to the pathophysiology as well. The introduction of 
either wild-type astrocytes, oligodendrocytes, or microglia into global Mecp2 knockout mice 
stabilized breathing patterns, increased lifespan, improved motor function, and normalized body 
weight [11-13]. Symptoms such as gastrointestinal dysmotility, hypoactivity, and bone 
abnormalities have been attributed to Mecp2 disruption in peripheral tissues as well [8]. Though 
considered to be a neurodevelopmental disorder, evidence indicates that Mecp2 is more 
important for maintaining mature cellular function than being necessary for determining cell fate 
[14]. Consistent with this idea, expression of WT Mecp2 in Mecp2-null males completely 
reverses symptoms [15]. 
The Mecp2 gene encodes for the protein MeCP2 that is only found in vertebrates [16]. 
MeCP2 is a nuclear protein that binds to methylated DNA, with the two most important 
functional domains being its methyl-binding domain (MBD) and its transcriptional repressor 
domain (TRD). MBD function has been demonstrated to be more important than TRD function 
in maintaining normal behavior as mutating the MBD domain in mice results in a complete null-
like phenotype whereas TRD mutations leads to a milder phenotype in mice [17]. The MBD 
domain allows MeCP2 to bind to methylated CpG locations of DNA [18], unmethylated DNA, 
though, to a lesser degree [19] and 5-hydroxymethylcytosine (5hmc) [20]. The TRD is thought to 
provide MeCP2’s activity as a gene silencer. AT-hook motifs may influence its ability to bind to 
DNA as well. 
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Originally thought to be a transcriptional repressor [21], later studies discovered MeCP2’s 
involvement in transcriptional activation and was classified as a transcriptional regulator [22]. 
There are two isoforms of MeCP2, MeCP2-e1, and MeCP2-e2 [23]. MeCP2-e1 is the common 
isoform found in the central nervous system (CNS) and is associated with RTT symptoms [24]. 
The protein often acts in conjunction with other proteins such as CREB1, HDAC, mSin3A, and 
NCOR/SMRT complexes to either silence or activate transcription [25-27]. As such, it targets 
dozens of genes directly and has innumerable indirect effects [28]. Other functions of MeCP2 
include chromatin reorganization by compaction that is independent of its ability to bind to 
methylated DNA [29, 30] and regulation of RNA splicing [31-33]. 
There are over 800 known disease-causing Mecp2 mutations [34]. Eight missense and 
nonsense mutations account for nearly 70% of cases of RTT, large deletions account for 7%, C-
terminal truncations account for 7%, and the remaining cases are caused by other unspecified 
mutations [35]. The eight common point mutations are R106W, R133C, T158M, R168X, 
R255X, R270X, R294X, and R306C. RTT-conferring mutations are typically de novo mutations 
of paternal origin [36] though there are rare cases of inherited mutations [37, 38]. In general, 
clinical severity is associated with the location of the mutation with those occurring earlier in the 
gene leading to more severe symptoms such as impaired motor function and language skills [35, 
39].  
2.1.2 X chromosome inactivation 
Clinical phenotype is not only determined by gene mutation, but also the amount of 
skewed X-chromosome inactivation [40]. MECP2 is located on the long arm of the X 
chromosome, which undergoes random silencing in females. Thus, females with RTT have 
somatic mosaicism containing a mixture of cells expressing the normal and mutant MECP2 
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alleles. Due to this phenomenon, clinical severity may vary from patient to patient even if they 
carry the same MECP2 mutation type [41]. Some cases have been identified in which the X 
chromosome expression has been skewed to favor expression of the normal allele over the 
disease-causing one [35]. In particular, patients with large deletions may be more likely to have 
an expression pattern favoring the wild-type copy subsequently leading to a better physical 
outcome [35]. 
2.1.3 Mouse models 
Knowing the disease-causing RTT mutations has led to the creation of animal models. The 
earliest and most prevalently used model is mouse though other animal models such as rats [42, 
43], zebrafish [44], and monkeys [45] are being developed. The most widely used and first 
mouse model of RTT was created in the lab of Adrian Bird, which has a deletion of exons 3 and 
4 on the Mecp2 gene [46]. This mutation results in no functional protein expression, and thus a 
complete knockout. This model has been well characterized behaviorally and cellularly. Another 
early established mouse model that is similar to the Bird mouse model is the Jae line [7].  
Male mouse models have been used more in studies though female mouse models are more 
representative of this disease. Male mouse models have several advantages over female models, 
such as the prevalence of a stronger phenotype, consistent manifestation of symptoms, and 
earlier occurrence of symptoms making mechanistic studies more feasible [46]. For example, 
mutant male mice develop overt symptoms around four weeks of age while symptoms are not 
typically as obvious until around 4-6 months of age in female mice. Studies have demonstrated 
that these mouse models recapitulate many human symptoms such as motor abnormalities, 
breathing abnormalities, and tremors [46, 47]. Disadvantages of mouse models of RTT are the 
recapitulation of speech pathology, cognitive impairments, anxiety-like behaviors, and social 
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behaviors. Assessment of speech capabilities and assessment of cognitive functions are difficult 
due to natural limitations of the mouse model and RTT mice.  
Mouse models with the common point mutations found in this disease have been created as 
well [27, 48-56], most of which confer phenotypes similar to human patients. Conditional 
knockout mice have further contributed to our understanding of the roles of different neuronal 
and other cellular types to symptom development in patients as well. Utilizing the Cre-lox 
recombination system mouse models with selective deletions in glutamatergic [57], GABAergic 
[9], aminergic, norepinephrinergic, serotonergic neurons [10], and astrocytes have been made 
[58]. Conditional knockout of Mecp2 in glutamatergic and GABAergic neurons led to 
phenotypes nearly identical to whole-brain knockouts of Mecp2, which indicate that the 
glutamate and GABA neurotransmitter systems play crucial roles in RTT symptom development 
[9, 57]. NEergic and serotonergic knockouts highlight Mecp2 contributions to specific symptoms 
such as motor abnormalities and anxiety-like behavior [10].  
2.2 Symptom Development  
2.2.1 Respiration and RTT 
Respiration is one of the essential functions of life. Breathing serves as a means of gas 
exchange, providing oxygen to cells in the body and removal of carbon dioxide. Breathing 
dysfunction is one of the prominent symptoms of RTT. Breathing abnormalities have been linked 
to cardiac arrhythmia as well as 27% of cases of sudden death in RTT [1]. Breathing dysfunction 
is often cited as a primary concern of parents and caretakers. This symptom develops early in life 
in these patients and lasts throughout their lifetime. The breathing dysfunction is characterized 
by periodic hyper and hypoventilation, as well as breath holds or apneas [59]. Breathing 
irregularities are seen commonly during wakefulness, but are less severe during sleep. Originally 
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thought to completely disappear during sleep, breathing disturbances were eventually discovered 
to still exist during sleep [60].  
2.2.1.1 Anatomy of respiration 
The necessary anatomy for breathing includes the mouth, nose, larynx, trachea, glottis, 
epiglottis, lungs, diaphragm, and intercostal muscles. The respiratory system is divided into the 
upper respiratory tract and the lower respiratory tract. The upper respiratory tract consists of the 
nose and pharynx. The lower respiratory tract consists of the larynx, trachea, bronchi, and lungs. 
The lungs of the lower respiratory tract are the primary drivers of respiration. Changes in 
thoracic volume are what drive the movement of air into and out of the lungs. During inspiration 
the volume of the lungs is increased due to contraction of the diaphragm located just beneath the 
lungs. Simultaneously, the external intercostal muscles contract, raising the ribs and sternum. 
Relaxation of the diaphragm leads to expiration and the internal costal muscles lower the ribs 
and sternum.  
Breathing consists of multiple phases: inspiration, postinspiration, and expiration. These 
different phases are controlled by different anatomical features as well as cellular aspects. 
Inspiration or inhalation is the inward movement of air primarily driven by the autonomic 
nervous system. Expiration or exhalation is the outward movement of air, primarily driven by 
passive mechanisms. Though both components are driven by involuntary mechanisms, they can 
be overridden by voluntary processes originating from the prefrontal cortex. Postinspiration is an 
aspect of breathing that serves as a way to coordinate other processes such as coughing, chewing, 
and talking. 
Four measures known as pulmonary volumes are used to assess the capacity and health of 
the lungs. Tidal volume is the amount of air inhaled or exhaled during one breath. Inspiratory 
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reserve volume is the amount of air that can be forcefully inhaled beyond the relaxed breathing 
state. Expiratory reserve volume is the amount of air that can be forcefully exhaled beyond 
passive expiration. The residual volume is the amount of air remaining in the lungs after a 
forceful expiration. Minute ventilation is another measure used to assess breathing capacity over 
time, which is calculated by multiplying the tidal volume by the breathing rate. 
Apneas, characterized by cessation of inspiratory activity, are a hallmark of breathing 
dysfunction in RTT patients [59]. In these patients, exhalation and inhalation are reduced by 25% 
and 10%, respectively [60]. During hyperventilation, however, their breaths tend to be deeper. 
Overall the breathing pattern, frequency, and amplitude are more variable in RTT patients 
compared to healthy individuals.  
2.2.1.2 Respiratory neurons in the brainstem 
Breathing is controlled by both voluntary and involuntary measures though primarily 
driven by the autonomic nervous system seated in the brainstem. Within the brainstem exist three 
general groups of respiratory neurons: the dorsal respiratory group, the ventral respiratory 
column (VRC), and the pontine respiratory group (PRG). The dorsal respiratory group located 
near the nucleus tractus solitaries (NTS) is thought to be responsible for rhythmic breathing 
activity. The ventral respiratory column is located within the ventrolateral medulla and is further 
subdivided into subregions. This group consists of inspiratory and expiratory neurons as well as 
premotorneurons and rhythm generating neurons. 
Within the rostral VRC exists the retrotrapezoid nucleus (RTN)/parafacial respiratory 
group (pFRG) which may be involved in rhythm generation [61], the Bötzinger complex (BötC) 
which facilitates the transition period between inspiration and expiration by generating post-
inspiratory activity [62, 63], and the preBötzinger complex (preBötC), which is the primary 
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rhythm generator for inspiratory activity [64]. The PRG is located in the rostral dorsolateral pons 
and contains the parabrachial complex and the Kölliker-Fuse (KF). 
Within the VRC are respiratory neurons that are responsible for respiratory pattern 
generation [64, 65]. As mentioned above, the VRC consists of the BötC, pre-BötC, rostral 
ventral respiratory group (rVRG), and caudal ventral respiratory group (cRVG) [66]. The NTS is 
a group of heterogeneous neurons based on electrophysiological properties, anatomy, and 
neurochemical content [67-69]. The NTS plays an essential role in integrating sensory 
information from multiple brain areas and producing a respiratory response [70]. Of particular 
interest, NTS neurons receive information about hypoxia located in the peripheral system and 
lung inflation [71].  
Respiratory neurons such as the preBötC project to premotor neurons, which in turn 
project to the phrenic motoneurons, which innervate the diaphragm or the intercostal muscles. 
Ablation or cessation of activity of pre-BötC neurons causes cessation of breathing though 
voluntary control of breathing may still be employed to continue breathing. The BötC modulates 
the activity of pre-BötC neurons and also is important for modulating post-inspiration. Recently, 
a newly identified nucleus was demonstrated to be necessary and sufficient for postinspiration 
[72]. The postinspiratory complex (PiCo) has autonomous and rhythm generating properties as 
well. 
2.2.1.3 Rett and respiratory nuclei 
Evidence indicates that dysfunction of neurons within both the forebrain and brainstem 
contributes to respiratory dysfunction in RTT, with proper functioning of brainstem neurons 
playing a major role at later stages [73]. Phrenic activity from in situ preparations from Mecp2-/Y 
mice has apneas with influence from the forebrain removed, emphasizing the importance of 
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brainstem dysfunction [73]. In addition, mice with Mecp2 removed in brainstem neurons, using 
conditional knockouts driven by the Hoxb1 gene, which is specific to the hindbrain, also display 
defects in respiratory activity [74]. Restoration of Mecp2 selectively in Hoxb1 expressing cells 
rescues many of the breathing abnormalities. 
Some studies have tried to identify key respiratory neurons within the brainstem that are 
important for maintaining normal breathing patterns in RTT. Dysfunction of the KF nucleus was 
discovered to be associated with prolonged apneas and abnormal postinspiratory activity [47]. 
Injections of glutamate into the KF caused prolonged apneas. A study by Viemari et al. showed 
that in vitro, neurons in the ventral respiratory group of Mecp2-/Y mice had irregular firing 
patterns [75]. Within the ventrolateral medulla, which contains the pre-BötC GABAergic 
function was found to be impaired, suggesting changes in firing activity of these cells [76]. 
Another study looked specifically at pre-BötC neurons in Mecp2-null mice and discovered 
deregulated Ca2+ homeostasis in these cells, which may affect cellular functioning [77]. 
A previous belief of the respiratory network in Mecp2 mutant mice was that these neurons 
were hypoactive, therefore leading to less drive for breathing. We have obtained evidence that, in 
fact, the respiratory network is overactive. In decerebrate Mecp2-/Y rats, breathing irregularities 
remain and the firing patterns of inspiratory and expiratory neurons are altered [43, 78]. Both 
expiratory neurons and inspiratory neurons firing durations are increased. Also, the number of 
neurons with postinspiratory activity is decreased.   
2.2.1.4 Modulators of breathing and RTT 
Neuromodulators play a significant role in breathing dysfunction in RTT as well. While 
passive breathing is set by rhythm generators within the brainstem, this activity can be 
modulated by other factors as well, such as voluntary processes originating from the forebrain as 
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well as chemicals. Numerous substances can modulate breathing activity, including monoamines 
such as norepinephrine (NE), serotonin (5-HT), and dopamine (DA) as well as peptides such as 
substance p, met-enkephalin, and neuropeptide Y. NE and 5-HT modulation originating from 
brainstem neurons especially play a significant role in breathing modulation. Amounts of the 
neurotransmitters NE and 5-HT in the CNS are decreased in RTT patients and mice [75, 79, 80].  
Manipulation of these systems improves respiratory symptoms. 5-HT1a receptor agonists, 
and selective serotonin reuptake inhibitors improve breathing abnormalities in Mecp2-/Y mice 
[81-85]. A primary modulator of respiratory activity under normal circumstances is 
norepinephrine (NE). Exogenous NE to in vitro preparations from Mecp2-null mice normalizes 
firing activity of respiratory neurons [75]. The selective NE reuptake blocker desipramine 
enhances the amount of overall NE available in the CNS and improves breathing dysfunction in 
Mecp2-/Y mice [86, 87] though its effects are less pronounced in patients [88].  
Six groups of NEergic neurons exist in the brain labeled A1-A7 and A6, also known as the 
locus coeruleus (LC) is the major provider of NE throughout the central nervous system. The LC 
is critical for proper development and functioning of breathing especially for facilitation of 
rhythmicity of pre-BötC neurons pacemaker cells [89-91]. Select NEergic receptors may 
significantly modulate breathing activity. There are several NE receptors α1, α2, β1, β2, and β3. 
There are three α1 subtypes: α1a, α1b, α1d as well as three α2 subtypes α2a, α2b, α2c. Among 
the different NE receptor subtypes, α2-adrenoceptors seem to play an important role in breathing 
modulation. Experiments in brain slices showed that blockade of α2-adrenoceptors significantly 
decreased respiratory neuron frequency and caused irregular activity patterns [92].  
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2.2.1.5 Modification of ventilation by gas 
LC response to hypoxia and hypercapnia are also important for proper ventilatory response 
to such conditions [93]. Carbon dioxide (CO2) is a major regulator of breathing. Increases in the 
amount of CO2, also known as hypercapnia causes increased ventilation in order to maintain 
normal systemic levels. CO2 is produced in cells as a waste product and diffuses into the 
bloodstream. CO2 reacts with water to ultimately create hydrogen ions and bicarbonate ions. 
When CO2 concentration increases in the blood, the pH is decreased making it more acidic. 
There are several neurons within the brainstem called chemoreceptors that detect changes in pH 
and modulate respiration. Decreases in pH beyond normal levels are what drive increased 
breathing activity. 
Normally, CO2 is produced by cells as a waste by-product and is cleared from the system 
in exchange for O2 in blood vessels. CO2 accumulation in the system increases the breathing rate 
to expel CO2 more quickly however, the minimal amount of CO2 necessary to stimulate 
increased breathing is defective in Mecp2 mutant mice. Normally, detectable at 3% CO2, the 
threshold in Mecp2 mutant mice is approximately 6%. This then causes a period of 
hyperventilation to clear the system, which overcorrects depleting O2 levels and is subsequently 
followed by hypoventilation to compensate. The LC is known to be a chemoreceptor and in one 
study, the LC was lesioned in mature rats, which did not change basal breathing frequency 
although the response to hypercapnia was impaired [93]. Similarly, impaired CO2 
chemosensitivity in Mecp2-null mice is associated with LC dysfunction [94]. 
Though chemosensitivity is impaired in Mecp2-null mice, enhancement of NE with 
desipramine improves chemosensitivity [94]. A likely culprit for the reduced sensitivity was 
discovered to be overexpression of Kir4.1 channels in LC cells. Similar to findings of NE’s 
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involvement in RTT chemosensitivity, another study showed that enhancing 5-HT by pretreating 
Mecp2-/Y mice with the SSRI citalopram improved CO2 chemosensitivity [95]. Chemosensitivity 
of astrocytes was reduced in Mecp2-/Y mice as well [96]. 
2.2.1.6 Alternative explanations for respiratory dysfunction in RTT 
In addition to brainstem neuronal dysfunction, other possible contributors to breathing 
abnormalities in RTT include impaired signaling from the upper brain and upper airway 
obstruction. Improvement of breathing function in RTT patients during sleep suggests that as 
forebrain activity decreases, so does signaling to the brainstem [60]. One study implicates upper 
airway obstruction in ventilatory irregularities in RTT as Mecp2-/Y mice show increased chest 
movements with no significant change in air volume, suggesting upper airway obstruction [97]. 
Other research has also demonstrated irregularities in post sigh activity in Mecp2 mutant mice, 
which is correlated with upper airway dysfunction [98]. One potential mechanism for airway 
obstruction is improper functioning of the tongue. The hypoglossal nucleus is responsible for 
controlling tongue movement and maintaining upper airway patency. In fact, alterations in the 
hypoglossal nucleus of Mecp2 mutant mice exist [99]. Glycinergic input to hypoglossal neurons 
is increased in Mecp2 mutant mice, possibly as a compensatory response to decreased 
GABAergic input seen throughout the entire CNS [99].  
2.2.2 Body weight, lifespan, and motor defects 
In addition to respiratory disturbances, Mecp2 mutant mice recapitulate many other robust 
symptoms of RTT, such as altered body weight, reduced lifespan, and motor impairment [46]. 
Decreased weight gain and growth are other common features of RTT [100, 101]. Mecp2-mutant 
male mice typically exhibit reduced body weight, while female heterozygotes exhibit increased 
body weight [46, 102]. Studies have demonstrated this effect to be influenced by genetic 
16 
background. Though the mechanisms remain unclear, these symptoms may be partially 
attributable to nutritional deficiencies caused by a combination of feeding difficulties, absorption 
problems, and altered metabolic functions in energy expenditure [100, 103]. A study implicated 
the brainstem in growth deficiencies by conditionally knocking out Mecp2 in hindbrain cells, 
which lead to decreased body weight in male mice [74]. 
RTT mice also have a general poor body condition with conditions such as disheveled fur 
and kyphosis, which may be homologous to scoliosis seen in patients [8]. Both patients and 
mouse models have decreased bone density and altered biomechanics, often leading to fractures 
during childhood in human patients [104-106]. One possible contributor to this is dysfunction of 
osteoblasts [107]. Male Mecp2-mutant mice often exhibit a poor condition early in life and 
ultimately have a shortened lifespan, typically living no longer than two months [46]. There are 
no reported effects on heterozygous female lifespan. Knockout of Mecp2 only in hindbrain 
neurons caused shortened lifespan, similar to whole-body knockouts implicating the autonomic 
nervous system in survival capability [74]. 
Gait abnormalities, as well as stereotypic hand movements such as handwringing, are 
examples of motor problems commonly seen in RTT patients. Mecp2-mutant mice exhibit robust 
symptoms such as ataxia, reduced motor coordination, and balance, hypoactivity, and hindlimb 
clasping [46, 108]. Interactions between the motor cortex, extrapyramidal system, and sensory 
neurons, such as proprioceptors, result in coordinated movement. Proprioception is the sense that 
allows detection of limb position, balance, force, and movement. Proprioception is necessary for 
navigating spaces and provides feedback to changes in the environment to inform the body on 
how to respond or compensate. Mesencephalic trigeminal (Me5) neurons provide propriosensory 
information about jaw muscles. Me5 neurons project to masseter muscles where stretch receptors 
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located on their processes detect muscle flexion. Me5 neurons also project to trigeminal motor 
neurons (Mo5), which project back to masseter muscles directly causing contraction. We have 
found that Me5 neurons are hyperexcitable in Mecp2-null mice, which likely contribute to their 
motor defects [109]. 
2.3 Cellular mechanisms underlying symptom development 
Changes in cellular functions and structure ultimately lead to behavioral consequences. 
Several changes in neuronal states are associated with symptom development in RTT. Changes 
in neurons include decreased soma size, reduced number of synapses, and altered dendritic spine 
morphology [110]. Before symptoms occur, cellular changes already manifest, some of which 
may be compensated enough to mask symptoms [111]. Evidence indicates that there is no 
increase in cell death, but reduced cell volume [112], which may account for the smaller brain 
size and microcephaly seen in patients. Contributing to reduced cell volume is altered dendritic 
spine morphology, which may be related to Ca2+ homeostasis and the expression of NMDA and 
AMPA receptors in the dendrites [113]. These components are involved in transcription and 
translation of necessary microskeletal structures of the cell [113]. 
Studies indicate that impairment of Mecp2 may impair neuronal differentiation and cell 
fate by affecting senescence [114, 115]. This evidence suggests that there may be structural 
abnormalities in the brains of RTT patients. However, reactivation of the Mecp2 gene during 
adulthood restored normal function to Mecp2-null mice, indicating that the basic structure and 
connections in the brain are intact and only the functioning of the brain is impaired [15]. 
2.3.1 Neurophysiology and RTT 
As structural components of neurons have been discovered to be compromised in Mecp2-
null cells so too has the functioning of these cells been altered. Significant concerns about 
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cellular changes are changes in neuronal output and information integration. The output of a 
neuron depends on the intrinsic membrane properties and its synaptic connections. Neuronal 
output affects behavior and changes in neuronal output lead to abnormal behavior and disease.  
Common methods to study functioning of neurons electrophysiological techniques such as 
whole-cell patch clamp. Patch clamp allows the study of electrical properties of cells known as 
electrophysiological properties. Electrophysiological properties of cells can be grouped into two 
main categories: passive membrane properties and active membrane properties. 
2.3.2 Passive membrane properties  
Passive membrane properties are electrical characteristics of a cell that determine a cell’s 
electrical signaling capabilities. These properties include resting membrane potential, 
capacitance, and input resistance.  Capacitance is a property of a cell that describes the plasma 
membrane’s function as a capacitor, storing electric charge. The capacitance of a cell is 
proportional to its size thus, a large cell has a large capacitance and requires more current to 
change its voltage. Thus, this property gives the observer an indicator of the size of the cell. 
Input resistance describes the relationship between current and voltage. Given an injected current 
to a cell, the voltage will change in a particular way described by Ohm’s law, V= I×R. Similarly, 
membrane resistance is dependent on the number of ion channels located in the area of the cell 
that is studied. Capacitance and membrane resistance together describe a cell’s time constant, 
which is the time that it takes for cell’s membrane potential to reach a steady state in response to 
input. 
With passive membrane properties, a cell may respond to current injection in a linear 
fashion, but once it passes a certain threshold, the cell responds differently, generating an action 
potential. The properties of the cell are then described as active membrane properties 
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categorizing how the cell behaves during a period of electrical activity.  Active membrane 
properties include firing frequency, rheobase, afterhyperpolarization, spike frequency adaptation, 
delayed excitation, and postinhibition rebound. 
2.3.3 Neuronal excitability and disease  
Dysfunction of membrane properties and their underlying protein channels are well 
documented to be associated with disease. Changes in intrinsic properties have been linked to 
output and function [116]. Many studies have focused on the mechanisms underlying changes in 
firing patterns. These changes have been linked to homeostasis under normal conditions, but 
these same mechanisms exist for pathological states as well. Alterations in neural excitability can 
lead to changes in transcription processes, neuronal communication, and plasticity. Some well-
studied examples of changes in membrane properties of neurons leading to pathology include 
epilepsy and Alzheimer’s disease [117, 118].  
Decreases in inhibitory inputs and a bias towards hyperexcitability have been linked to 
epilepsy [119]. Changes in firing patterns towards phasic firing have been implicated in epilepsy. 
In a mouse model of epilepsy, pyramidal neurons of hippocampus shifted from approximately 
3%, showing burst firing properties to 48% in the epilepsy model, mostly driven by changes in 
Ca2+ sensitivity and K+ currents [120]. The mouse model of epilepsy highlights changes that lead 
to increased hyperpolarization and increased sensitivity to excitatory inputs [121, 122]. Studies 
on pain have shown lower threshold to elicit action potentials especially in conditions such as 
diabetes-associated allodynia, inflammation and, Man on Fire Syndrome [123, 124]. Allodynia 
and hyperalgesia in streptozocin-induced diabetic rats were associated increased Na+ current 
[123]. Similarly, studies show increased excitability in dorsal root ganglion neurons is associated 
with inflammatory pain [125, 126]. 
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Studies demonstrating reduced GABA and increased glutamate have suggested a 
relationship between autism spectrum disorders and neuronal hyperexcitability [127, 128]. Fast 
phasic firing is important for regulating network timing [129]. This leads to regulation of whole-
scale oscillations. Cells need to be synchronized in order to create detectable waveforms from 
techniques such as EEG. Any variability in EEG waveforms indicates desynchronization as often 
found in autism spectrum disorders [130].  
2.3.4 Intrinsic membrane properties and RTT 
Changes in several membrane properties are altered in Mecp2 mutant mice as well, 
resulting in a shift in the excitation/inhibition balance underlying symptom development [131, 
132]. Hyperexcitability, especially in the brainstem and hippocampus and substantia nigra is one 
of the major electrophysiological properties associated with RTT symptom development [133, 
134]. Though neuronal hyperexcitability is linked with symptoms in RTT changes in excitability 
are region specific. For example, the forebrain of Mecp2-null mice shows hypoexcitability [135]. 
LC cells, located in the brainstem, are hyperexcitable showing both increased spontaneous firing 
activity and increased firing activity in response to current injections [136, 137]. Other altered 
membrane properties include increased inward rectification, action potential threshold, action 
potential morphology, after hyperpolarization, delayed excitation, and spike frequency 
adaptation [137]. These changes indicate that basal level of LC activity is altered as well as 
responses to synaptic signals. Mechanisms underlying changes in membrane properties largely 
depend on changes in protein expression of the corresponding properties.  
2.4 Molecular substrates underlying membrane properties 
Neuronal excitability or the electrical activity of neurons resulting in action potentials is 
the underlying cause of communication among neurons. Neuronal excitability is determined by 
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intrinsic factors as well as network connections. Intrinsic neuronal excitability is set by the 
expression of different ion-permeable proteins on the surface of the neuron. The ions most 
important for setting the excitability of neurons include Na+ and K+ ions, with K+ being the major 
contributor to neuronal excitability.  
2.4.1 Sodium channels  
Voltage-gated sodium (Nav) channel's main function is to generate the upstroke of action 
potentials. Once changes in neuronal voltage are detected, Navs are opened allowing an influx of 
Na+ ions, and a rapid and transient depolarization of the cell. Different amounts of Nav channels 
expressed and different subtypes expressed affect the kinetics of the action potentials. In addition 
to Navs that are responsible for rapid depolarizations of cells, there are Navs that produce a 
longer lasting and noninactivating Na+ current called the persistent sodium current (INaP). Nav 
dysfunction is associated with diseases such as epilepsy, hyperalgesia, Dravet’s Syndrome and 
Alzheimer’s disease [118, 123, 138]. The hyperpolarization-activated cyclic nucleotide–gated 
(HCN) channel is a cationic channel, though not exclusive to Na+ ions, they are the primary 
mediator of the resultant current Ih. Reduction of HCN channels and Ih have been linked to 
epilepsy [121, 122]. 
HCN channels are altered in RTT as well. In Mecp2-null mice, Me5 neurons have 
increased excitability and decreased firing threshold which is associated with downregulated 
HCN channel expression [109]. Concurrently, sodium channel subunit is shifted potentially as a 
compensatory mechanism to counterbalance decreased Ih current. Similarly, Ih is downregulated 
in CA1 neurons of the hippocampus [139, 140]. 
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2.4.2 Potassium channels 
Potassium channels serve to largely set the resting membrane potential of cells as well as 
repolarize neurons after the initiation of action potentials. They are permeable to K+ ions and 
typically allow the efflux of K+ in neurons. There are several different types of K+ channels, such 
as voltage-gated potassium (Kv) channels, Ca2+ activated channels, and tandem pore domain K+ 
channels. Kvs primarily serve to restore a cell’s resting membrane potential after activation of 
Nav channels, which together form the action potential. There are also Kvs not directly involved 
in shaping the morphology of action potentials, but play significant roles in regulating firing 
activity of cells as well as their responses to synaptic messages. These channels include inwardly 
rectifying K+ (Kir) channels, delayed rectifier K+ channels, A-type K+ channels, and slowly 
activating K+ channels.  Given the various K+ channel functions, their dysfunctions are associated 
with many different neurological diseases such as neural degeneration, schizophrenia, 
inflammatory pain, and epilepsy [141] [125, 126]. In RTT, Kir 4.1 channels are overexpressed in 
LC neurons, which is associated with decreased pH sensitivity [94]. However, Kir 4.1 expression 
is decreased in astrocytes [142]. In Mecp2-null mice small/intermediate-conductance Ca2+ 
sensitive K+ channels were found to have a reduced response to anoxic conditions, which was 
caused by decreased intracellular Ca2+ [143]. 
2.4.3 Calcium channels 
Voltage-gated Ca2+ channels (Cav) are activated by depolarization and allow the influx of 
Ca2+ ions due to the electrochemical gradient. Subtypes include N-type, P-type, L-type, R-type, 
and T-type Cavs. Cavs are associated with burst firing, signal integration and activation of the 
afterhyperpolarization phase of an action potential by activating Ca2+ activated K+ channels. 
This is important for setting a cell’s firing rate. In addition, downstream second messenger 
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systems are also substantially affected by alterations in the function of these channels. Their 
dysfunction has been linked to epilepsy and hyperalgesia [120]. In hippocampal CA1 neurons, 
Ca2+ currents mediated by voltage-sensitive Ca2+ channels are increased in Mecp2-null mice 
[139, 140]. 
2.4.4 Synaptic contributions to cellular excitability 
In addition to changes in intrinsic membrane properties, changes in synaptic connections 
contribute to changes in cellular excitability as well. Classical neurotransmitters such as 
glutamate, GABA, and glycine produce immediate voltage changes on receiving cells. Glutamate 
is the major excitatory neurotransmitter throughout the central nervous system causing excitatory 
postsynaptic potentials (EPSPs).  GABA is the major inhibitory neurotransmitter throughout the 
central nervous system causing inhibitory postsynaptic potentials (IPSPs). Glycine is another 
inhibitory neurotransmitter that plays a more important role in the lower brainstem and the spinal 
cord though it can be found sparsely in areas of the forebrain [144]. All three of these 
neurotransmitter systems act on ionotropic receptors causing fast responses on the postsynaptic 
cells.  
2.4.5 GABA in the brainstem and RTT 
A lot of focus has been given to the involvement of GABA in the shift in 
excitation/inhibition balance in RTT in the development of symptoms. Decreased GABA IPSCs 
have been found in Mecp2-null mice in several different nuclei, including, but not limited to the 
LC, NTS, and KF [145-147]. Extensive studies on GABA neurons in RTT models have not been 
performed, but some studies looking at subclasses of GABA neurons have provided insight into 
how Mecp2 disruption affects their activity. One of the primary ways to classify GABA neurons 
is by their expression of buffering systems and other substances. Based on this classification 
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system, major subgroups of GABA neurons include parvalbumin (PV), calcitonin neurons, and 
somatostatin (SOM) expressing neurons. PV neurons appear to be the most widespread 
throughout the CNS. PV cells in Mecp2-null mice are hyperexcitable [148]. Selective deletion of 
Mecp2 in either PV or SOM also causes RTT-like phenotypes [149]. 
Classical neurotransmitters such as GABA and glutamate also cause slower responses by 
binding to g protein-coupled receptors (GPCRs) also known as metabotropic receptors. They 
affect cellular activity by indirectly altering the activity of targeted cells as well as their 
responses to stimuli. Non-classical neurotransmitters also known as neuromodulators such as 
NE, 5-HT, acetylcholine (Ach), and DA, primarily bind to GPCRs as opposed to ionotropic 
receptors. GPCRs interact with G proteins located on the cellular membrane. There are numerous 
G proteins, some of the more important ones being Gi, Gs, and Gq. Activation of g proteins may 
have several effects on the cell including inhibition and stimulation, which are done by 
interactions with ion channels and second messenger systems. GPCRs located on synaptic 
terminals serve to regulate neurotransmitter release, typically by interacting with ion channels. 
2.4.6 GIRK channels 
One common ion channel target of GPCRs is the G-protein-gated inwardly rectifying 
potassium (GIRK) channel, which is expressed widely throughout the brain. GIRK is a class of 
K+ permeable ion channels that are a part of the larger inwardly rectifying K+ (Kir) channel 
family. Kir channels pass an inward K+ current at membrane voltages below K+ equilibrium 
potential (EK), typically around -90 mV, that is much larger than the outward K+ current that 
passes through the channel above EK. This is in contrast to other K+ channels that primarily only 
allow current to flow outward.  
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There are four isoforms of GIRK channels GIRK1, GIRK2, GIRK3, and GIRK4. GIRK 
channels 1-3 are found primarily in the CNS, while GIRK4 is primarily located in the heart. The 
GIRK channels 1 and 2, often expressed together, are the primary subunits expressed in the brain 
[150]. GIRK channels form tetramers and typically as heterotetramers [151]. GIRK2 is the only 
subunit that can form homotetramers [152]. There exist splice variants of GIRK2, GIRK 2a, b, 
and c [153, 154]. There are also GIRK1 splice variants, but those have not been studied as well. 
Splice variants for GIRK3 and 4 are unknown.  
The subcellular location of GIRK channels depends on the subunit. In pyramidal neurons, 
GIRK2a and GIRK2c proteins overlap in their subcellular expression locations, but GIRK2a is 
mostly located on the soma and proximal dendrites while GIRK2c is reportedly located 
uniformly throughout the entire neuron [155]. The GIRK1d splice variant expression was shown 
to reduce the current of other GIRK channels when co-expressed [156]. In addition, substantia 
nigra and VTA neurons do not express GIRK1 channels, but express GIRK2a-GIRK2c and 
GIRK2a-GIRK3 combinations, which are less sensitive to Gβγ again emphasizing the importance 
of subunit expression patterns. GIRK channel density in axons, soma, and dendrites differ [157]. 
Thus, different GIRK channel isoforms have differential subcellular expression patterns and that 
activation of different isoforms could potentially have different cellular effects. 
2.4.7 Pre- and postsynaptic modulation of GIRK channel 
Though one of the unique properties of the GIRK channel is its ability to pass inward K+ 
ions, its main contribution is the efflux of K+ ions upon activation. This is because most neuronal 
resting membrane potentials are likely above EK; therefore, GIRK channel activation leads to 
hyperpolarization and inhibition of a cell. Basal activity of GIRK channels contributes to resting 
membrane potential by 2-8 mV in dorsal raphe and hippocampal neurons [158, 159]. GIRK 
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channels function to regulate both pre- and postsynaptic cells. GIRK channels are known to act 
as in conjunction with autoreceptors, regulating the amount of neurotransmitter released from the 
releasing cell. They serve as negative feedback mechanisms, inhibiting or decreasing further 
release from the cell. These presynaptic autoreceptors are located on axon terminals and bind the 
neurotransmitter released from the cell. Another mechanism by which GIRK channels cause self-
inhibition is through dendro-denritic interactions or autaptic transmission [160].  
Their activation on postsynaptic cells leads to inhibition, as well. In both cases the effect of 
GIRK channel activation is a slower sustained effect as compared to ionotropic receptor 
activation. Communication is not always one way though. Postsynaptic cells can inhibit 
neurotransmitter release from presynaptic cells by activation of GIRK channels via retrograde 
signaling. Common retrograde signaling molecules include endocannabinoids, nitric oxide or CO 
[161-163]. GIRK channels have been implicated in many different physiological phenomena as 
well as pathophysiological conditions. They play an important role in epilepsy, opioid addiction, 
and Parkinson’s disease. GIRK2 knockout mice develop seizures and have reduced pain 
alleviation mediated by opioids [164, 165].  
2.5 Pharmaceutical interventions to RTT 
There are currently no approved treatments for RTT though treatment tends to focus on 
physical therapy and managing symptoms. A wide range of drugs have been tested for their 
potential use as treatment though they have been met with modest success. A study 
demonstrating that the expression of normal Mecp2 during the adult stage completely reverses 
RTT symptoms is encouraging for seeking treatments to rescue this disease [15]. As such, many 
approaches involve manipulating genetic and molecular processes such as correcting the gene 
mutation or affecting transcription. Given the progressive development of gene-editing 
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technologies such as CRISPR [166], that goal is increasingly becoming within reach. Alternative 
methods targeting the gene include using read-through compounds for nonsense mutations such 
as R168X, R270X, and R294X [167, 168], antisense oligonucleotides [169], and reactivation of 
the inactive X chromosome in cells expressing the mutant form of Mecp2 [170]. As of yet, these 
strategies are still in the early development stages and more accessible methods are needed. 
More readily available treatment options target pathways downstream of MECP2. 
Evidence indicates that dysfunction of neurotransmitter signaling plays an important role in 
symptom development, and thus many therapies have sought to compensate for these defects.  
These treatment options have targeted neurotransmitter systems such as GABA, glutamate, NE, 
and 5-HT.  Many have shown promise, especially in treating breathing problems in mice, but 
have had modest success in humans. Serotonin receptor 1a agonists and selective serotonin 
reuptake inhibitors (SSRIs) improve respiratory symptoms in mice [83, 84]. Desipramine, the 
NE reuptake blocker, decreased the occurrence of apneas, improved sensitivity to mild 
hypercapnia, and extended the lifespan of male Mecp2-null mice [86, 87, 94], but failed to 
improve the breathing patterns of human patients [88]. The GABA system has been highly 
targeted for treatments, as well. Benzodiazepines, GABA reuptake blockers, and extrasynaptic 
GABAA agonists are some of the tested drugs for this system [82, 171, 172]. Brain-derived 
neurotrophic factor (BDNF) as a treatment method has also been of particular interest [173]. As 
these treatment options target processes downstream of MECP2, they have had varying degrees 





RTT is a neurodevelopmental disorder that affects approximately 1: 10,000 females 
worldwide. People with RTT develop serious clinical problems such as motor impairment, 
seizures, and breathing dysfunction. The disease leads to a reduced quality of life, and breathing 
abnormalities specifically are associated with sudden death. Currently, there is no cure for RTT. 
Therefore, further studies need to elucidate the disease mechanisms and identify potential 
treatments. 
The majority of studies of RTT have been performed in male mouse models though it is 
primarily a disease that afflicts females. Using male mouse models has several advantages, 
including manifestation of severe phenotypes, quick manifestation of symptoms, and low 
interindividual variability of symptoms. Female Mecp2 mutant mice, however, have varying 
degrees of symptom severity and late age of observable symptoms. To provide informative and 
translatable information, there needs to be a way to reliably identify and study female Mecp2 
mutant mice that are representative of RTT in humans. Therefore, information on how to identify 
symptomatic female mice can lead to studies with more translatable potential. 
Mutations in the gene MECP2 account for over 90% of cases of RTT. Approximately 
800 known mutations of the gene cause RTT though they cause different symptom severities. 
The different gene mutations may have unique molecular and cellular consequences. Treatments 
for RTT must, therefore, take into account the different effects of the gene mutations. The most 
widely used model of RTT uses a Mecp2 gene mutation that is not commonly found in human 
patients. Thus, our studies testing the cellular effects of one of the most common MECP2 gene 
mutations, R168X, is significant for providing mechanistic information for potential targeted 
treatments. 
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Brainstem dysfunction is a major contributor to symptom development in RTT. 
Hyperexcitability of brainstem neurons has been strongly linked to RTT symptoms originating 
from the autonomic nervous system, especially breathing abnormalities. Several drugs have been 
tested targeting reducing neuronal hyperexcitability, but have had modest success in treating 
human patients. Therefore, identification of a treatment method to reduce neuronal excitability 




4 MATERIALS AND METHODS 
4.1 Animals  
Experiments were performed in male Mecp2 R168X/Y and Mecp2 Bird/Y mice, because the 
male mice with Mecp2 disruption offer a reliable Mecp2 -defective condition that is not always 
available in heterozygous females owing to the uncontrolled X-chromosome inactivation [174, 
175]. We also used symptomatic and asymptomatic females to validate our findings from male 
mice. To breed the Mecp2 R168X mice, female heterozygous Mecp2 R168X mice were purchased 
from the Jackson Laboratory (strain name: B6J;129S6.MeCP2R168X, stock no: 024990, Bar 
Harbor, ME) and crossbred with WT males with the same genetic background. Offspring were 
genotyped using the PCR protocol from Jackson Laboratory. Female heterozygous Mecp2 tm1. 
1Bird mice (strain name: B6.129P2(C)-Mecp2 tm1.1Bird/J, stock no: 003890, Jackson Laboratory) 
were crossbred with WT C57BL/6 or Swiss Webster Mecp2 +/Y males to produce Mecp2 Bird/Y 
male offspring. Male wild-type (WT) littermates of the Mecp2 R168X/Y and Mecp2 Bird/Y mice 
served as controls. GAD-ChR mice were generated by cross-breeding the strain of GAD2-Cre 
mice (Gad2tm2(cre)Zjh/J, Jackson Laboratory SN 010802) with the ChR2-eYFP-LoxP strain 
(B6;129S-Gt(ROSA)26Sortm32(CAG-COP4*H134R/EYFP)Hze/J, Jackson Laboratory SN 12569). Female 
and male offspring were used in the following studies. All experimental procedures in the 
animals were conducted in accordance with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals, and approved by the Georgia State University Institutional 
Animal Care and Use Committee. 
4.2 Measurements of Breathing Activity by Plethysmography 
Breathing activity was recorded from unrestrained conscious mice without anesthesia in 
an ~50 ml plethysmograph chamber connected to an empty reference chamber. The mice were 
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given normal room air at a flow rate of 20 ml/min and allowed to acclimate to the chamber for 
15 min before recording. Breathing activity of the mice was recorded for 20- 30 min, while the 
mouse was monitored using a video camera. In the first set of experiments, thirteen mice were 
tested on 2-4 occasions with at least a month before subsequent testing. In later experiments, 
mice were injected with a single dose of CPS (30 mg/kg, i.p.) or saline 30 min before 
experiments. Frequency variation was calculated by the standard deviation divided by the mean 
frequency. At least 200 breaths were measured which were composed of three or four randomly 
sampled stretches of at least 50 consecutive breaths. Apneas were counted during the entire 
duration of the 20 min recording. A breath was considered an apnea if the breath lasted more 
than twice the duration of the previous breath. Periods of movement and potential sleep were 
recognized with video records and excluded from analysis. Data were stored and analyzed offline 
using Clampfit 10.3 software (Molecular Devices, Sunnyvale, CA). 
4.3 CO2 Ventilation 
In the experiments, mice were allowed to adapt to the chamber for 20min when the 
plethysmograph chamber was ventilated with room air. After a 10 min recording of the baseline 
breathing activity with normal air, the ventilation air was switched to 3% CO2 by balancing with 
normal air in room air for 5 minutes at a speed of 50ml/min. The gas mixture was obtained from 
a local supplier containing 21% O2. The total volume of the plethysmograph chamber was 
~40ml. Since the mouse occupied most of this volume, a steady state of hypercapnia was reached 
within one minute as in previous experiments [94].  
4.4 Grip Strength and Grid Walking Tests 
In the grip strength test, an individual mouse was held by its tail to allow the forelimbs to 
grasp a metal bar connected to a force-electricity transducer (CB Sciences, Inc., Milford, MA). 
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The mouse was slowly pulled up vertically until the grip was released. This was repeated three 
times for each mouse. The maximal forced reached was measured as the grip strength. The 
measurements were converted to grams and all three trials were averaged.  
In the grid walking test, a mouse was placed in a rigid box (32 cm × 20 cm × 20 cm), 
which was elevated to 50 cm high. The device had a metal mesh floor with 11 × 11 mm 
openings. The mouse walking was recorded using a video camera for 5 min. Forepaw and 
hindpaw foot faults were counted when a limb missed the metal floor bar (0.5mm in diameter) 
completely and went through the grid hole. The foot fault ratio was calculated by the overall foot 
faults divided by the total steps (including both forelimbs and hindlimbs). 
4.5 Survival Rate 
All animals counted for survival rate were kept in the same housing condition as for other 
mice. Their survival time was counted from birth to in-cage death or when the mice reached a 
humane endpoint that was determined by a staff member in the animal facility at Georgia State 
University. 
4.6 Channel Expression   
Rat GIRK1 (Kir3.1) cDNA (GenBank accession no. U01071), rat GIRK4 (Kir3.4) cDNA 
(GenBank accession no. X83584), rat GIRK2 (Kir3.2) cDNA, and GFP cDNA constructs were 
expressed in human embryonic kidney (HEK) cells as detailed in our previous reports [176, 177]. 
The HEK cells were cultured as a monolayer Dulbecco's modified Eagle's medium (DMEM)–
F12 with 10% fetal bovine serum and penicillin–streptomycin added at 37°C with 5% CO2. The 
HEK cells were split twice weekly and transfected using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA, USA) with 2 μg GIRK channel cDNA. 0.5 μg green fluorescent protein (GFP) 
cDNA (pEGFP‐N2, Clontech, Palo Alto, CA, USA) was added to the cDNA mixture to identify 
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transfected cells. Cells were disassociated from the monolayer using 0.25% trypsin ∼24 h post‐
transfection. The re-suspended cells were added on to 5 × 5 mm cover slips in a 35 mm Petri 
dish. The cells were then incubated at 37°C for an additional 24–48 h before experiments.  
4.7 HEK Cell Recordings  
Single‐electrode whole‐cell voltage clamp was performed on HEK cells at room 
temperature. Patch pipettes were pulled with a Sutter pipette puller (model P-97, Novato) and 
had an open tip resistance of 3-6 MΩ. Seals >1 GΩ were obtained from GFP expressing cells 
before breaking into the whole‐cell mode. Currents were recorded with the amplifier Axopatch 
200B (Molecular Devices, Sunnyvale, CA, USA). Recordings were lowpass filtered (2 kHz, 
Bessel, 4‐pole filter, −3 dB), digitized (10 kHz, 16‐bit resolution), and stored on a computer for 
later data analysis using pCLAMP 10 software (Molecular Devices). Bath solution contained (in 
mM): KCl 20, NaCl 140, CaCl2 0.5, EGTA 5, MgCl2 5.46, HEPES 10. Pipette solution contained 
(in mM): KCl 130, NaCl 20, CaCl2 0.5, MgCl2 2, K2ATP 2.56, Li2GTP 0.3, HEPES 10.  
4.8 Brain Slice   
Brain slices were prepared as described previously [137]. In brief, mice were anesthetized 
with isofluorane and decapitated. The brainstem was obtained rapidly and placed in an ice-cold, 
sucrose-rich artificial cerebrospinal fluid (sucrose aCSF) containing (in mM) 220 sucrose, 1.9 
KCl, 0.5 CaCl2, 6 MgCl2, 33 NaHCO3, 1.2 NaH2PO4 and 10 D-glucose. The solution was 
bubbled with 95% O2 balanced with 5% CO2 (pH 7. 40). Transverse pontine sections (160–200 
μM) containing the LC area and DTN were obtained using a vibratome sectioning system (1000 
Plus, Vibratome, St. Louis, MO). The slices recovered in normal aCSF (in mM) containing 124 
NaCl, 3 KCl, 2 CaCl2, 2 MgCl2, 26 NaHCO3, 1.3 NaH2PO4 and 10 D-glucose at 33°C for 30 
min. The slices were then kept at room temperature before recording. During recordings, slices 
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perfused with oxygenated aCSF at a rate of 2 ml/min and maintained at 32–35°C (Warner 
Instruments, TC-344B) in a recording chamber. 
4.9 Electrophysiology   
Whole cell current-clamp and voltage clamp studies were performed on cells visualized 
using a near-infrared charge-coupled device camera. Cells with resting membrane potentials 
(Vm) more negative than −40 mV and action potential (AP) amplitudes >65 mV were considered 
healthy and used for further analysis. Patch pipettes were pulled with a Sutter pipette puller 
(model P-97, Novato) with a resistance of 3–6 MΩ. The slice was perfused with normal aCSF 
and superfused with 95% O2 and 5% CO2 at 34°C. The pipette solution for current-clamp 
experiments contained (in mM) 130 potassium-gluconate, 10 KCl, 10 HEPES, 2 Mg-ATP, 0.3 
Na-GTP, and 0.4 EGTA (pH 7.30). For voltage clamp experiments, the pipette solution 
contained 50 mM KCl, 85 mM CsCl, 2 mM MgCl2, 2 mM magnesium-ATP, 1 mM sodium-
GTP, 10 mM HEPES, and 0.5 mM EGTA (pH 7.30) Recorded signals were amplified with a 
Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA), digitized at 10 kHz, filtered at 
1 kHz, and collected with the Clampex software. The temperature was maintained at 33°C during 
recording by a dual automatic temperature control (Warner Instruments, Hamden, CT). 
In voltage-clamp and current clamp studies synaptic blockade was achieved by addition 
of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist 6-
cyano-7-nitroquinoxaline-2, 3-dione (CNQX, 10 μM), the N-methyl-D-aspartate (NMDA) 
receptor antagonist DL-2-Amino-5-phosphonopentanoic acid (DL-APV, 10 μM), the glycine 
receptor antagonist strychnine (1 μM) and in some experiments the GABAA receptor antagonist, 
bicuculline (20 μM), was added to the external solution. Recorded signals were amplified with 
an Axopatch 700B amplifier (Molecular Devices, Union City, CA), digitized at 10 kHz, filtered 
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at 2 kHz using the low-pass filter, and collected with the Clampex 10.3 data acquisition software 
(Molecular Devices). Additional drugs used include 20 μM Phaclofen, and 300 μM BaCl2. 
4.10 Field Potential Recordings   
Field potentials were recorded with glass-coated tungsten microelectrodes with 20-30 µm 
tip exposure. The signals were amplified (Electro 705 Electrometer, World Precision 
Instruments; differential AC amplifier model 1700, AM Systems), digitized (Digidata 1440A, 
Axon Instruments. Inc.), recorded (Clampex 10.3 software, Molecular Devices), and analyzed 
offline (Clampfit 10.3 software, Molecular Devices). Data analysis was done with an average of 
at least 50 traces of signals synchronized to the onset of stimulating light pulses. 
4.11 Optogenetics   
GABAergic neurons were detected in brain slices with YFP expression using 
fluorescence microscopy in excitation at 480 nm and emission at 520 nm (green). 
Optostimulation was performed by using a xenon arc light source with a high-speed switcher 
(Lambda DG-4, Sutter Instruments, Novato, CA). The light source was connected to the 
incident-light illuminator port of the microscope, and delivered blue light through a 470 nm 
bandpass filter. The 2-100 ms pulse trains were triggered by a Grass Stimulator S88 Dual Output 
Square Pulse Stimulator (Natus Medical Inc, Can).  
4.12 Data Analysis   
The electrophysiological and plethysmograph data were analyzed with Clampfit 10.3 
software (Molecular Devices) and voltage clamp (or IPSC) data were analyzed using Mini 
Analysis Program 6.0.7 software (Synaptosoft). Group distribution was tested with the k-means 
clustering statistics analysis (http://scistatcalc.blogspot.com/2014/01/k-means-clustering-
calculator.html). Data are presented as means ± SE. Statistical analysis was performed using 
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Mann-Whitney U test, Kruskal-Wallis Analysis, One-Way ANOVA with Tukey’s post hoc, two-
way repeated measures ANOVA, Two-Way Mixed-Model ANOVA, with Bonferroni post hoc, 
and two-tailed Student's t-test. Greenhouse-Geisser correction was applied when the assumption 




5 RESULT 1: BREATHING ABNORMALITIES IN A FEMALE MOUSE MODEL OF 
RETT SYNDROME 
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F. Oginsky, Chun Jiang. Breathing abnormalities in a female mouse model of Rett syndrome. 
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5.2 Abstract 
Rett Syndrome (RTT) is a female neurodevelopmental disease with breathing 
abnormalities. To understand whether breathing defects occur in the early lives of a group of 
female Mecp2+/− mice, a mouse model of RTT, and what percentage of mice shows RTT-like 
breathing abnormality, breathing activity was measured by plethysmography in conscious mice. 
Breathing frequency variation and apnea in a group of Mecp2+/− females displayed a distribution 
pattern similar to Mecp2−/Y males, while the rest resembled the wild-type mice. Similar results 
were obtained using the k-mean clustering statistics analysis. With two independent methods, 
about 20% of female Mecp2+/− mice showed RTT-like breathing abnormalities that began as 
early as 3 weeks of age in the Mecp2+/− mice, and were suppressed with 3% CO2. The finding 
that only a small proportion of Mecp2+/− mice develop RTT-like breathing abnormalities 
suggests incomplete allele inactivation in the RTT-model Mecp2+/− mice. 
38 
5.3 Introduction 
Rett Syndrome (RTT) is a neurodevelopmental disease caused by disruptions of the X-
linked gene encoding methyl-CpG-binding protein 2 (MeCP2) which affects approximately 1 in 
10,000 live female births [5, 178, 179]. Males with this defect are usually unable to survive after 
birth. In addition to autistic symptoms, people with RTT show breathing disturbances, such as 
irregular breathing, apnea, hyperpnea, apneusis, Valsalva breathing, air swallowing, etc. [59, 
180]. The breathing disorders contribute to the high rate (26%) of sudden and unexpected death, 
and developmental abnormalities in the brain [1]. 
Many of these breathing abnormalities exist in male mice with the Mecp2 gene deletion 
(Mecp2−/Y), which are typically used as mouse models of RTT. Our previous studies have shown 
that the Mecp2−/Y mice lose their sensitivity to moderate hypercapnia, while their sensitivity to 
severe hypercapnia is normal [94]. The defect seems to be, at least partially, due to the abnormal 
expression of pH-sensitive K+ channels in the central nervous system [94]. As a result, CO2 
levels are detected only when hypercapnia becomes severe in the mice, leading to a transition 
from hypoventilation to hyperventilation. After the excessive CO2 is removed from the body, 
hypoventilation is resumed. The defective response to moderate PCO2 thus can lead to periodic 
hyper- and hypoventilation as seen in RTT. 
Nearly all RTT patients are female, whereas the majority of previous studies on the RTT 
breathing phenotype were performed on male mouse models with disruption of the Mecp2 gene. 
The rationale behind such an approach is that the RTT-like symptoms can be reliably produced 
in these Mecp2−/Y males, whereas they may be variable in female mice heterozygous with the 
Mecp2 gene deletion (Mecp2+/−) owing to random X-chromosome inactivation. However, the 
female animal models of RTT resemble more closely human RTT patients with respect to their 
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genotypes. Therefore, information generated in Mecp2−/Y male mice needs to be validated in 
Mecp2+/− females. 
Indeed, breathing defects have been found in female Mecp2+/− mice older than 2-month, 
which is an age equivalent to full grown humans [82, 102]. However, it is unclear what 
percentage of Mecp2+/− females develop RTT-like breathing abnormalities, whether the 
breathing abnormalities occur in the early lives, and whether they deteriorate with growth. It is 
still challenging to address these questions, because the random X-chromosome inactivation 
causes only a certain number of mice to develop breathing disorders with variable symptoms, 
which requires subtle experimental approaches to reveal. In our previous studies, we have 
developed several methods for the analysis of the breathing irregularities in Mecp2-null mice, 
including population analysis of breathing variation and CO2 sensitivity [94]. Therefore, we 
performed these studies to address above questions in heterozygous Mecp2+/− female mice. 
5.4 Results 
5.4.1 Breathing frequency variation in female Mecp2+/− mice.  
Because of the random expression of the X chromosome, Mecp2+/− heterozygous females 
may have breathing phenotypes resembling either wild-type (WT) or Mecp2−/Y mice. Therefore, 
we measured breathing activity of the females in comparison with the WT, which consisted of 
normal male and female mice (Mecp2+/+) without Mecp2 deletion. The WT mice (n=56) showed 
stable breathing activity. In contrast, a clear variation in f and apnea were seen in Mecp2-null 
males (Mecp2−/Y)( Fig. 5.1b).  
To analyze our data quantitatively, the variation index was used to measure the breathing 
f variations as we described previously [94]. Consistent with our previous observations [94], the 
f variation was much greater in the Mecp2−/Y mice showing a significant difference from the WT 
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mice. In contrast, certain Mecp2+/− females showed breathing activity like the Mecp2−/Y mice, 
while the breathing of others resembled the WT (Fig. 5.1c), suggesting that they are not a single 
homogenous group. 
To understand whether the Mecp2+/− females consist of two different populations with 
respect to their f variation and what percentage of mice develop RTT-like f variation, we studied 
the distribution of f variation index against ages. Firstly, we analyzed the f variation distribution 
of WT and Mecp2−/Y mice. Figure 5.2a shows that the f variation of the Mecp2−/Y mice tends to 
distribute between 0.2 and 0.4, while that of the WT is mostly located around 0.1 or between 0 
and 0.2. Using the mean value and standard deviation of these data, Gaussian distribution curves 
were made to represent the data (Fig. 5.2a).  
We then compared the f variation index of Mecp2+/− females with the Gaussian 
distribution curves obtained from WT and Mecp2−/Y mice. Figure 2b shows that although most of 
the Mecp2+/− females have f variations around 0.1 similar to the WT mice, several Mecp2+/− mice 
seem to have much greater f variations that were around 0.3. To prove that the apparent 
separation of the f variation index within the Mecp2+/− female population is statistically 
significant, we performed the k-means clustering analysis. Using this statistics method, the f 
variation index of the Mecp2+/− females was divided into two populations (Fig. 5.2c).  
A characteristic of the f variation distribution is the overlap without a clear boundary, 
which was seen not only among Mecp2+/− females (Fig. 5.2b) but also between WT and 
Mecp2−/Y mice (Fig. 5.2a). Therefore, we chose to use the interception of the two Gaussian 
distribution curves as the threshold to separate the RTT-like phenotype (Mecp2−/Y[R]) from the 
normal (Mecp2−/Y[N]), which is 0.2 in f variation as shown in Figure 5.2b. Statistically, the f 
variation of Mecp2−/Y[R] mice was not different from that of RTT-like phenotype mice isolated 
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by the k-means clustering (Mecp2−/Y[r]) (Fig. 5.2d). So was Mecp2−/Y[N] mice in comparison 
with Mecp2−/Y[n] mice. Therefore, the interception of the two Gaussian distribution curves seems 
to be a useful way to separate the Mecp2+/− females with different breathing f variations. 
With such a pooling, 10 of 75 female Mecp2+/− mice tested (13%) were separated from 
the rest. These Mecp2−/Y[R] mice had f variation index 0.24 that was highly significant different 
from the WT (f variation index = 0.11). The f variation of the Mecp2−/Y[R] had no significant 
difference from the Mecp2−/Y males (f variation index = 0.27) (Fig. 5.2e). The f variation index 
of the other group of Mecp2+/− females, Mecp2+/− [N] (0.10), resembled more the WT (Fig. 5.2e). 
Similar results were obtained by pooling Mecp2+/− mice using the k-means clustering, in which 
13 (17%) showed significantly high f variation (Fig. 5.2f). Statistical analysis of these two results 
showed no significant difference (P>0.05, χ2 test) although the k-means clustering seems more 
sensitive. 
Based on these results obtained with two independent methods, it is likely that the 
Mecp2+/− females are not made of a homogenous group regarding breathing irregularity, and 
approximately 15% of Mecp2+/− females show RTT-like phenotype. 
5.4.2 Apnea  
A prolonged period of breathing cessation known as apnea is a hallmark of breathing 
dysfunction in RTT patients. Although apneas are seen in the WT mice as well, the frequency of 
the apneas was extremely low. In contrast, Mecp2−/Y mice displayed high frequencies of apneas. 
Therefore, the apnea count was measured as number of events per hour (apneas / h), and used as 
another indication of the severity of breathing abnormality. Apnea was defined as at least one 
breath cycle missing as described above. The entire recording period (30 min) under normal air 
ventilation was used to analyze the number of apneas.  
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Similar to f variations, apnea counts showed normal (Gaussian) distributions in the WT 
and Mecp2−/Y mice, in which most WT and Mecp2−/Y mice were separate from each other 
although overlaps were also found (Fig. 5.3a). At the interception of two Gaussian distribution 
curves, a threshold value (38 apneas / h) was obtained. Using the threshold value, the Mecp2+/− 
females were divided into two groups (Fig. 5.3b). Of 75 female Mecp2+/− mice tested, 17 (23%) 
were isolated as Mecp2+/−[R] with RTT-like phenotype from the rest Mecp2+/−[N]. A similar 
number (17, 23%) was isolated using the k-means clustering method (Fig. 5.3c). Statistical 
analysis of these two results showed no significant difference (P>0.05, χ2 test). Consistently, 
apnea counts of the Mecp2+/−[R] was not significantly different from Mecp2+/−[r] (P>0.05, Fig. 
5.3d). 
After the median and IQR were calculated, Kruskal-Wallis test showed that the 
Mecp2+/−[R] females had no significant difference from Mecp2−/Y mice, but were significantly 
different from the WT in their medians (Fig. 5.3e). Vice versa for the rest of the WT-like 
Mecp2+/− females, i.e., Mecp2+/−[N]. Separation of apneas / h with the k-means clustering 
analysis was identical to the threshold results (Fig. 5.3f).  
Since Mecp2+/− mice with significant f variations were not completely identical to those 
with severe apneas, Mecp2+/− mice with either alone could have mild breathing abnormality. 
Therefore, we further examined these mice. Using k-means clustering analysis, 9 of 75 Mecp2+/− 
mice (Mecp2+/− [v]) showed significant f variation and apneas (Fig. 5.4a,b). With respect to f 
variation and apnea, the Mecp2+/− [v] mice were not significantly different from the Mecp2+/−[R] 
mice, but significantly different from the Mecp2+/−[N] females (Fig. 5.4c,d).  
Similar results were obtained based on the threshold levels determined, in which 7 of 75 
Mecp2+/− mice showed both significantly high f variation and apneas. The Mecp2+/− [v] mice 
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isolated with the threshold did not show more severe f variation and apnea from the Mecp2+/−[R] 
mice either (not shown). These results thus suggest that either f variation or apnea may be used 
to isolate Mecp2+/− female mice with RTT-like breathing abnormalities from the rest females. 
5.4.3 Age Contribution 
The severity of breathing disorders seen in Mecp2+/− mice may change with the 
progression of age. Based on the threshold levels identified, age differences between Mecp2+/− 
mice at ages of 3 weeks to 6 months were analyzed between RTT-like and normal Mecp2+/− mice 
with respect to f variation and apnea (Fig. 5a,b). Both breathing abnormalities were seen in mice 
3-weeks of age, and the occurrence ratio of breathing abnormalities did not increase with aging 
(from 3 weeks to 6 months). Approximately13% of Mecp2+/− females displayed RTT-like 
breathing f variations, and approximately 28% of Mecp2+/− mice showed RTT-like levels of 
apnea in this age range in these groups of mice, which were very close to our observation in the 
general mouse population above. The f variation and apnea counts were compared in the three 
age groups between RTT-like and normal Mecp2+/− mice. The RTT-like Mecp2+/− mice showed 
significantly higher levels of f variation and apnea counts than the normal Mecp2+/− mice (Fig. 
5c,d). Out of the 13 Mecp2+/− mice that were retested, 5 initially displayed apnea counts above 
the determined threshold of 38 apneas/h, but upon subsequent testing did not display apnea 
numbers above the threshold. One Mecp2+/− mouse did not display apneas above the threshold, 
but upon subsequent testing showed a number of apneas above the threshold. The other 7 
Mecp2+/−never displayed a number of apneas above the threshold (data not shown). 
5.4.4 Response to CO2 
To determine if exposing RTT-like Mecp2+/− mice to an elevated level of CO2 reduces 
the severity of their breathing abnormalities, a concentration of 3% CO2 was delivered to the 
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animals in a plethysmograph chamber. Apneas and the f variation were analyzed in the same way 
as described above. RTT-like Mecp2+/− mice displayed a significant reduction in f variation 
when exposed to 3% CO2 (Fig. 5.6a). Their irregular breathing was resumed when the high CO2 
ventilation stopped. In normal air, the f variation was 0.24 in RTT-like Mecp2+/− mice. These 
breathing variations were suppressed with 3% CO2 leading to an f variation 0.14 (Fig. 5.6b), 
which was not significantly different from the baseline f variation (0.12) of WT mice. The RTT-
like Mecp2+/− mice also displayed a significant reduction in apneas from 56 counts/h to 18 
counts/h when exposed to 3% CO2 (Fig. 5.6c,d). Frequent apneas returned when the 
plethysmograph chamber was ventilated with room air.  
5.5 Discussion 
It is known that RTT-like breathing disorders start to manifest themselves in Mecp2−/Y 
males at 3 weeks of age [46, 181], while a fraction of Mecp2+/− mice also begin to display the 
same symptoms at this age as shown in the present study. Since most Mecp2+/− mice do not 
develop breathing irregularities due to random X-chromosome inactivation, the demonstration of 
the breathing disorders in the present study should have an impact on the understanding of RTT 
with female animal models.  
Like human patients with RTT, Mecp2−/Y male mice show hypoventilation, apneas 
followed by brief hyperventilation and increased variability in breathing frequency [182]. 
Several different studies have shown the alleviation of these irregularities by increasing the 
availability of neurotransmitters or their precursors such as norepinephrine, GABA and serotonin 
[82, 86, 183]. Our previous studies have indicated that breathing patterns of the Mecp2−/Y mice 
can improve in response to elevated CO2. We have found that these mice lose their sensitivity to 
moderate hypercapnia, while their sensitivity to severe hypercapnia appears normal. The 
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Mecp2−/Y mice do not respond to moderate hypercapnia, and display hypoventilation and 
breathing irregularities as under normocapnic condition. The breathing patterns may not allow an 
adequate clearance of CO2 leading to a buildup of systemic CO2 or the development of severe 
systemic hypercapnia. Because the mice have a decent sensitivity to severe hypercapnia, they 
then hyperventilate so that the excess CO2 is removed from the body. These events seem to occur 
periodically in the Mecp2−/Y mice as seen in patients with RTT [94].  
In one study, the percentage of Mecp2+/− mice that showed apnea levels significantly 
greater than WT mice were studied from 8 to 12 weeks of age. The percentage of these Mecp2+/− 
increased from 20% at 8 weeks to 50% at 12 weeks of age. [184]. The occurrence of apneas 
unaffected by age were detected in female Mecp2+/− mice 4-14 months old and periodic 
breathing defects have been demonstrated in 9-month-old female Mecp2+/− mice [82]. 
Concerning the lifespan of mice, it is unclear whether the defects in the old female mice might 
involve biological processes that are rather different from the early development of RTT patients. 
A recent study has demonstrated a great number of apneas in Mecp2+/− female mice when 
compared to WT [102], in which breathing irregularities were found in Mecp2+/− mice 
approximately 2 months old. At this age, mice are fully mature, and Mecp2−/Y male mice have a 
low survivability rate. Apparently, the age does not correlate well with the early onset of RTT in 
humans. In another study, breathing abnormalities were observed in Mecp2+/− mice 6-17 months, 
which were reduced by the selective 5HT-1a agonist, F15599 [183].  
Mecp2+/− mice display a range of symptoms, while the severity of RTT-like abnormalities 
is typically more difficult to characterize compared to Mecp2−/Y males that have a clean 
knockout of the Mecp2 gene with more obvious symptoms. To identify Mecp2+/− females with 
breathing abnormalities we have studied the distribution patterns using two independent 
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methods. Our data suggest that two populations of Mecp2+/− mice exist, one with a phenotype 
resembling WT and another displaying a significant RTT-like breathing phenotype. These two 
populations can be separated based on objective and quantifiable measures of breathing 
parameters. With these measures, a substantial number of Mecp2+/− mice display breathing 
abnormalities as severe as those seen in Mecp2−/Y males. These breathing abnormalities, though, 
appear to be less severe in the general population of Mecp2+/− mice by comparison to Mecp2-null 
males due to random X-inactivation and varying MeCP2 protein levels.  
Our results have shown that severe breathing defects take place as early as 3 weeks of 
postnatal age in female Mecp2+/− mice. These abnormalities were not studied in earlier age 
because of technical limitations in handling premature pups of both sexes. Despite this, our 
results suggest that the occurrence age for the breathing abnormalities seems comparable to that 
of Mecp2−/Y males. About 13% of Mecp2+/− mice develop irregular breathing, less than 25% of 
mice show frequent apneas, and ~10% females have both defects. Since none of these figures are 
close to the prediction of random X-inactivation (~50%), it is possible that the Mecp2 gene is not 
completely inactivated in 50% of female heterozygous mice.  
Our previous studies have shown that Mecp2−/Y mice have impaired central 
chemosensitivity. The mice do not respond to moderate CO2 levels, but their sensitivity to high 
PCO2 is normal. This defect leads to periodic hyper- and hypoventilation as seen in RTT patients 
[94]. Hypoventilation, frequent apneas and irregular/ineffective breathing tend to produce 
systemic hypoxia, while hypoxia is known to be a major risk factor for the maldevelopment of 
the central nervous system that occurs in RTT patients. Hypoxia has also been shown to cause 
vasoconstriction by the suppression of Kv2.1 channels [185]. Similar to Mecp2−/Y mice, the 
Mecp2+/− female mice with severe RTT-like symptoms respond well to the hypercapnic 
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challenge. Their breathing becomes regular with a significant reduction in apnea events when 
their breathing air contains 3% CO2. Therefore, the application of high CO2 may alleviate the 
deleterious consequences of breathing abnormalities in RTT patients. Interestingly, female 
Mecp2+/− mice between 4 months and 19 months are found to have a higher hypercapnia-
response threshold, and the CO2 chemosensitivity is improved in Mecp2-null male mice by 
increasing the availability of serotonin [95]. Together, these findings suggest the feasibility to 
correct the breathing disorders with a CO2 intervention, which seems useful in the therapeutical 
design for RTT as the consequence of the breathing disorders may not be limited to systemic 
hypercapnia.  
5.6 Conclusions 
In conclusion, Mecp2+/− female mice can be separated into two groups resembling WT 
and Mecp2−/Y males, respectively. In mice with RTT-like disorders, breathing irregularities begin 
to manifest themselves during the early lives of the Mecp2+/− mice before reaching adulthood. In 
the other group, the breathing phenotype remains similar to WT mice. We have shown that 
breathing abnormalities in Mecp2+/− mice occur earlier than previous studies have shown and the 
occurrence rate is less than 20%.The variable severities and occurrence rate of breathing 
irregularities in the general population of Mecp2+/− mice may be due to random X-inactivation, 
resulting in variable amounts of MeCP2 protein. These breathing irregularities can be largely 
reduced under hypercapnic ventilation. Therefore, these findings indicate that the severity of 
breathing abnormalities can be reliably distinguished from non-disease breathing phenotypes and 




Figure 5.1 Mecp2+/+ and Mecp2−/Y mice show typical normal and abnormal breathing patterns, respectively. 
a.) Mecp2+/+ mice exhibit normal inspiration (downdraft) and expiration breathing patterns. b.) Mecp2−/Y mice 
display stereotypical irregular breathing patterns. Arrows indicate an example of apnea. c.) An example trace of a 
Mecp2+/− mouse that exhibits normal breathing patterns. d.) An example trace of a Mecp2+/− mouse that exhibits 










Figure 5.2 Separation of Mecp2+/− mice based on f variation.  
a.) The f variation distribution of both WT (n=56) and Mecp2−/Y (n=13) mice against ages showed typical Gaussian 
distributions. WT mice are represented as open circles, Mecp2−/Y mice are represented as black triangles. b.) The f 
variation distribution of Mecp2+/− mice show two peaks that fit fairly to the Gaussian distributions of WT and 
Mecp2−/Y mice in (a). The vertical line at 0.20 indicates the intersection point that was used as a threshold to 
Mecp2+/− mice with and without breathing f variation. Of 75 Mecp2+/− mice, 52 individual Mecp2+/− female mice 
were tested. Thirteen were tested two to four times with no less than a month between tests. c.) Mecp2+/− mice were 
separated based on the k-means clustering method. RTT-like Mecp2+/− mice are represented as black triangles, and 
WT-like Mecp2+/− mice are represented as open triangles. d.) RTT-like Mecp2+/− and WT-like Mecp2+/− mice 
indicated by the threshold level show no significant differences from those indicated by the k-means clustering 
method. e.) With the threshold separation, 13 Mecp2+/− mice (Mecp2+/−[R]) showed f variation like the Mecp2−/Y, 
which have significant difference from the WT but not the Mecp2−/Y mice. The rest WT-like Mecp2+/− mice 
(Mecp2+/−[N], n=62) showed no significant difference in f variation from the WT. f.) When the f variation was 
separated using the k-means clustering method, the RTT-like Mecp2+/− mice (n=13, Mecp2+/−[r]) have significant 
difference from WT (n=56) but not from Mecp2−/Y mice. Vice versa for the WT-like Mecp2+/− mice (Mecp2+/−[n], 





Figure 5.3 Separation of Mecp2+/− mice based on number of apneas.  
a.) Both WT (n=56, open circles) and Mecp2−/Y (n=13, black triangles) mice show typical Gaussian distributions of 
the number of apneas. b.) Mecp2+/− mice are represented as black squares. The vertical line represents the separation 
level at 38 apneas / h. c.) Mecp2+/− mice were separated based on the k-means clustering method. RTT-like 
Mecp2+/− mice (n=17) are represented as black triangles, and WT-like Mecp2+/− (n=58) mice are represented as 
open triangles. d.) RTT-like Mecp2+/− and WT-like Mecp2+/− mice indicated by the threshold level show no 
significant differences from those indicated by the k-means clustering method. e.) When separated using the 
determined threshold level, Mecp2−/Y mice and the RTT-like Mecp2+/− mice  have no significant difference and WT 
(n=56) and the WT-like Mecp2+/− mice (n=58) have no significant difference. Data is presented as median ± IQ (* P 
<0.05, *** P <0.005) f.) When separated based on the number of apneas using the k-means clustering method 
Mecp2−/Y (n=13) mice and the RTT-like Mecp2+/− mice (n=17) have no significant difference and WT (n=56) and 





Figure 5.4 RTT-like Mecp2+/− mice with both significant f variation and apneas. 
a,b.) Mecp2+/− mice with significant f variations and apneas (Mecp2+/−[v], large diamond) indicated by the k-means 
clustering analysis were compared with Mecp2+/− mice showing significant f variation only (Mecp2+/−[r], gray 
triangles). Regarding severity of f variations, Mecp2+/−[v] mice were not significantly different from Mecp2+/−[r]. 
c,d.) Severity of apnea was not significantly different between Mecp2+/−[v] and Mecp2+/−[r] either. Data are 






Figure 5.5 Severity and occurrence rate of breathing irregularities in Mecp2+/− mice. 
a.) The ratio of RTT-like Mecp2+/− mice to WT-like Mecp2+/− mice based on f variation separation during the 
different age groups. b.) The ratio of RTT-like Mecp2+/− mice to WT-like Mecp2+/− mice based on the number of 
apneas/h separation during the different age groups. c.) The severities of f variation of the Mecp2+/− during the 
different age groups. Data is presented as means ± SE (*** P <0.005) d.) The numbers of apneas/h of the Mecp2+/− 






Figure 5.6 Mecp2+/− mice show reduced severities of breathing irregularities in response to 3% CO2.  
a.) Representative traces of a Mecp2+/− mouse during normal air ventilation, 3% CO2, and normal air washout. b,c.) 
Statistical analysis was performed in Mecp2+/− mice and WT mice. Significant suppression of f variation (b,c) and 
apnea (d,e) was found with 3% CO2. Normalized f variation (c) and apnea (e). Data is presented as means ± SE (* P 





6 RESULT 2: Defects in brainstem neurons associated with breathing and motor 
function in the Mecp2R168X/Y mouse model of Rett syndrome 
These results have been published: Christopher M. Johnson, Weiwei Zhong, Ningren Cui, Yang 
Wu, Hao Xing, Shuang Zhang, and Chun Jiang. Defects in brainstem neurons associated with 
breathing and motor function in the Mecp2R168X/Y mouse model of Rett syndrome. Am J 
Physiol Cell Physiol, 2016. 311(6): p. C895-C909. 
6.1 Acknowledgements 
This work was supported by the NIH (NS073875).  
6.2 Abstract 
Rett Syndrome (RTT) is an X-linked neurodevelopmental disorder caused mostly by 
disruption of the MECP2 gene. Among several RTT-like mouse models, one of them is a strain 
of mice that carries an R168X point mutation in Mecp2, and resembles one of the most common 
RTT-causing mutations in humans. Although several behavioral defects have previously been 
found in the Mecp2R168X/Y mice, alterations in nerve cells remain unknown. Here we compare 
several behavioral and cellular outcomes between this Mecp2R168X/Y model and a widely used 
Mecp2Bird/Y mouse model. With lower body weight and shorter lifespan than their wild-type 
littermates, the Mecp2R168X/Y mice showed impairments of breathing and motor function. Thus 
we studied brainstem CO2 chemosensitive neurons and propriosensory cells that are associated 
with these two functions, respectively. Neurons in the locus coeruleus (LC) of both mutant 
strains showed defects in their intrinsic membrane properties, including changes in action 
potential morphology and excessive firing activity. Neurons in the mesencephalic trigeminal 
nucleus (Me5) of both strains displayed a higher firing response to depolarization than their WT 
littermates, likely due to a lower firing threshold. Because the increased excitability in LC and 
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Me5 neurons tends to impact the excitation-inhibition balances in brainstem neuronal networks 
as well as their associated functions, it is likely that the defects in the intrinsic membrane 
properties of these brainstem neurons contribute to the breathing abnormalities and motor 
dysfunction. Furthermore, our results showing comparable phenotypical outcomes of 
Mecp2R168X/Y mice with Mecp2Bird/Y mice suggest that both strains are valid animal models for 
RTT research. 
6.3 Introduction 
Rett Syndrome (RTT) is an X-linked neurodevelopmental disorder with a morbidity rate 
of about 0.01% in female live births. In addition to autistic features, RTT patients typically 
exhibit symptoms of breathing dysfunction and motor impairment. Approximately 90% of cases 
of RTT are caused by disruptions in the gene encoding the methyl-CpG binding protein 2 
(MeCP2) protein, a transcriptional regulator.  
Since the discovery of the defective MECP2 gene in the development of RTT, several 
mouse models have been created, which recapitulate many RTT features [7, 24, 46, 51]. One of 
the most commonly used mouse models in RTT research is the strain of Mecp2tm1.1Bird/J mice 
with Mecp2 knockout. Also known as Mecp2Bird mice, they carry a large deletion of exons 3 and 
4 rendering the protein non-functional [46]. The current understanding of the effects of the 
Mecp2 disruption on RTT-like symptoms such as breathing abnormality, motor dysfunction, 
cognitive impairment and early death is mainly derived from this mouse model. Although these 
findings made in Mecp2Bird mice are important, they need to be validated in other animal models. 
This is particularly significant when therapeutic modalities are aimed to formulate as the ultimate 
goal of RTT research. 
56 
Unlike engineered gene disruptions, several naturally occurring Mecp2 mutations may 
cause Mecp2 disruptions to different degrees. One of them is the R168X point mutation [38]. 
The R168X mutation, found in 8-12% of RTT patients as one of the most common RTT-causing 
mutations, results in a premature truncation of the MeCP2 protein that presumably might retain 
some functionality [186, 187]. Therefore, it is necessary to study cellular and molecular 
mechanisms for RTT in animal models carrying such a mutation. Indeed, a mouse model with 
the R168X mutation in the Mecp2 gene (Mecp2R168X mice) has been developed recently [52]. 
Studies in this mouse model have revealed several behavioral defects including motor function, 
respiration, cognition, and anxiety [188-190]. These findings are encouraging as they warrant 
further studies on the cellular consequences of the R168X mutation. 
Several previous studies have shown that Mecp2 disruption alters the excitation- 
inhibition balance of neuronal networks, and meanwhile reduces the availability of certain 
neurotransmitters in the CNS [132, 191]. In locus coeruleus (LC) neurons, the main providers of 
norepinephrine (NE) in the CNS, we have found that the Mecp2Bird mice show cellular 
dysfunction manifested as defects in intrinsic properties, synaptic inputs, NE-biosynthesis 
enzyme expression, and CO2 chemosensitivity [94, 136, 137, 147, 192-194]. These as well as the 
fact that the LC neurons play a role in central CO2 chemoreception and breathing regulation 
suggest that validating some of these findings in another mouse model with a natural Mecp2 
disruption such as the R168X mutation may benefit the understanding of the neuronal basis for 
autonomic dysfunction in RTT.  
Because the R168X mutation may potentially result in a partially functional protein 
product as opposed to the non-functional MeCP2 protein in Bird mice, it is possible that the 
phenotype of the R168X mouse model is less severe than the Bird mouse model. To elucidate 
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how the R168X mutation affects neuronal intrinsic properties and the severity of RTT-like 
symptoms we compared breathing abnormalities and motor dysfunction, two of the most 
consistent and reproducible phenotypes, between Mecp2R168X and Mecp2Bird mice, and studied 
the cellular mechanisms associated with these phenotypes. Our results indicated that Mecp2R168X 
and Mecp2Bird mice share most RTT-like defects at behavioral and cellular levels, suggesting that 
the partially truncated MeCP2 protein with the R168X mutation may not be functional, at least in 
two types of brainstem neurons and their associated functions. 
6.4 Results 
6.4.1 Observable RTT-like characteristics 
Like Mecp2Bird/Y mice, all Mecp2R168X/Y mice displayed stereotypical hindlimb clasping 
(Fig. 6.1A). They also had a smaller body size than WT male littermates (Fig. 5.1B). When the 
body weight was compared, Mecp2R168X/Y mice weighed much less (8.9 ± 0.7 g, n = 13) in 
comparison to their WT littermates at four weeks of age (17.1 ± 1.1 g, n = 7; P < 0.001), which 
resembled Mecp2Bird/Y mice in the same age (20.9 ± 1.7 g, n = 9) vs their WT littermates (27.8 ± 
1.2 g, n = 8; P < 0.01) (Fig. 6.1C1). Note that Mecp2R168X/Y mice were generally smaller than 
Mecp2Bird/Y mice, owing to perhaps their genetic background as previously demonstrated to 
influence body weight [102]. To eliminate the effect of genetic background, Mecp2R168X/Y and 
Mecp2Bird/Y were normalized to their WT littermates. After normalization, Mecp2Bird/Y showed a 
significantly higher body weight (0.8 ± 0.1, n = 9) than the Mecp2R168X/Y mice (0.5 ± 0.0, n = 13; 
P < 0.01) (Fig. 6.1C2). 
We also compared the lifespans of these two strains of mice under the same housing 
condition. The lifespan of 22 Mecp2R168X/Y mice was recorded and compared with 18 of their 
WT littermates. The Mecp2R168X/Y mice started dying at 33 days of age, and 50% of them died on 
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day 52 (Fig. 6.1D). In contrast, none of the WT mice died in the study period (3 months). The 
50% death rate of Mecp2Bird/Y mice was 55 days (Fig. 6.1E). When the ratio of survival vs death 
was compared with the χ2 test, we did not find any statistical difference between Mecp2R168X/Y 
and Mecp2Bird/Y mice (P > 0.05). 
6.4.2 Breathing Disturbances 
Breathing disturbances are some of the major symptoms found in human RTT patients 
and mouse models. We have previously shown that breathing frequency variation and apnea rate 
can be reproducibly measured and compared between Mecp2Bird/Y and WT mice [94, 172]. Using 
these measures, we tested and compared breathing disturbances in Mecp2R168X/Y and Mecp2Bird/Y 
mice.  
Both Mecp2R168X/Y and Mecp2Bird/Y mice displayed frequent hyper- and hypoventilation 
(Fig. 6.2A1-B2). Quantitatively, the breathing irregularity was analyzed by averaging >200 
breaths. The obtained standard deviation was then divided by the arithmetic mean as an 
indication of breathing frequency variation [94]. The Mecp2R168X/Y mice had significantly higher 
breathing frequency variation (0.33 ± 0.05, n = 7) than their WT littermates (0.11 ± 0.02, n = 5; P 
< 0.01), which were comparable to Mecp2Bird/Y (0.27 ± 0.02, n = 11) vs their WT littermates 
(0.11 ± 0.02, n = 11; P < 0.001) (Fig. 6.2C1). After normalizing to WT levels, no significant 
difference was found between Mecp2R168X/Y (2.9 ± 0.5, n = 7) and Mecp2Bird/Y mice (2.4 ± 0.2, n 
= 11; P >0.05) (Fig. 6.2C2).  
Frequent apneas were observed in both strains of mice with Mecp2 disruption. Apnea 
counts were higher in Mecp2R168X/Y (130.3 ± 31.3 apneas / h, n = 7) than in their WT littermates 
(1.2 ± 0.8 apneas / h, n = 5; P < 0.01). Similar breathing abnormality was seen in Mecp2Bird/Y 
(123.5 ± 8.9 apneas / h, n = 11) over the WT (23.9 ± 7.3 apneas / h, n = 11; P < 0.001) (Fig. 
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6.2D1). Because the average apnea rate in some of the WT was too low (nearly zero) to make 
regular normalization, we analyzed the difference in apnea counts of Mecp2R168X/Y and 
Mecp2Bird/Y mice vs their WT littermates. In the study, apnea counts from each mutant mouse in 
both strains were subtracted by the population mean of apnea counts of WT mice, which were 
then averaged and compared between Mecp2R168X/Y (130.3 ± 31.3 apneas / h, n = 7) and 
Mecp2Bird/Y mice (123.5 ± 8.9 apneas / h, n = 11). No statistical difference was found with such a 
comparison (P >0.05) (Fig. 6.2D2). 
6.4.3 Muscle Strength and Motor Coordination  
Another major feature of RTT is motor dysfunction seen in both human patients and 
mouse models. The motor dysfunction manifests itself as impairment in muscle strength and 
motor coordination [195]. Thus, we assessed the muscle tone and motor coordination, using the 
grip strength test and the grid-walking test. At four to five weeks of age the grip strength of 
Mecp2R168X/Y (48.6 ± 4.4 g, n = 12) was significantly lower than their WT littermates (60.3 ± 4.5 
g, n = 7; P < 0.05) (Fig. 6.3A1). Similar reduction in grip strength was observed in Mecp2Bird/Y 
mice (57.7 ± 3.4 g, n = 12) compared to their WT littermates (89.6 ± 3.3 g, n = 7; P < 0.001). 
There was no significant difference between Mecp2R168X/Y and Mecp2Bird/Y mice when the data 
were normalized to the WT values (0.8 ± 0.1, n = 12 in Mecp2R168X/Y; 0.6 ± 0.0, n = 12 in 
Mecp2Bird/Y; P >0.05) (Fig. 6.3A2).  
These mice with Mecp2 disruption also showed a higher percentage of foot faults than 
their WT littermates. The foot faults averaged 8.8 ± 1.1 % (n = 6) in Mecp2R168X/Y and 4.6 ± 0.9 
% (n = 6) in their WT littermates (P < 0.05) (Fig. 6.3B1). Similarly Mecp2Bird/Y mice showed 5.5 
± 0.9 % (n = 6) foot faults in comparison to the WT (2.1 ± 0.2 %, n = 6; P < 0.01). After 
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normalization to the WT average, however, there was no significant difference between 
Mecp2R168X/Y (1.9 ± 0.2, n = 6) and Mecp2Bird/Y mice (2.7 ± 0.4, n = 6; P >0.05) (Fig. 6.3B2). 
6.4.4 Passive Membrane Properties of LC Neurons 
Human RTT patients and mouse models show autonomic dysfunction especially 
breathing abnormalities known to involve the NE system in the central nervous system (CNS) 
[75, 79, 191]. In the CNS, most NE modulation is derived from the locus coeruleus (LC), where 
neurons show abnormal intrinsic membrane properties in the Mecp2Bird/Y mice [137]. The 
demonstration of significant breathing abnormalities in Mecp2R168X/Y mice opened a question as 
to how the Mecp2R168X/Y mutation affects membrane properties of LC neurons. Thus, we 
performed whole-cell recordings in brain slices, and compared the intrinsic membrane properties 
of these cells between the mutant mice and their WT littermates.  
LC neurons from Mecp2R168X/Y and WT mice showed a typical nonlinear relationship of 
membrane potentials vs current injections (I-V) with no post-inhibition rebound (Fig. 6.4A1-B2). 
The membrane potentials of LC neurons in Mecp2R168X/Y averaged (-43 ± 1.1 mV, n = 14) in 
comparison to cells from WT mice (-47.5 ± 1.8 mV, n = 14; P < 0.05). These resembled LC 
neurons in Mecp2Bird/Y mice (-45.0 ± 1.1 mV, n = 7) vs the WT (-49.4 ± 1.0 mV, n = 5; P < 0.05) 
(Fig. 6.4C1). When normalized to WT levels, Mecp2Bird/Y cells did not show a significant 
difference (0.9 ± 0.0, n = 7) from the Mecp2R168X/Y (0.9 ± 0.0, n = 14; P > 0.05) in membrane 
potentials (Fig. 6.4C2). The average input resistance of LC neurons was not significantly 
different between WT and Mecp2R168X/Y or Mecp2Bird/Y mice, although neurons in null mice 
tended to have a higher input resistance (Fig. 6.4D1). There was no significant difference in input 
resistance between Mecp2R168X/Y and Mecp2Bird/Y mice after normalization (Fig. 6.4D2).  
61 
The nonlinear I-V relationship indicated that these cells also have inward rectification 
(IR). We have previously shown that in male Mecp2Bird/Y mice LC cells have enhanced IR, 
attributable to increased Kir 4.1 expression, which likely contributes to the resting membrane 
potential and dampens neuronal hyperexcitability [137]. Furthermore, enhanced inward 
rectification may minimize inhibitory input to the cell to correct its hyperexcitability. The inward 
rectification ratio was thus calculated by dividing input resistance at −70 mV by that at −100 mV 
as described previously [137]. The rectification ratio of LC neurons was higher in Mecp2R168X/Y 
mice (2.0 ± 0.2, n = 15) than in WT (1.5 ± 0.1, n = 14; P < 0.05), which were similar to 
Mecp2Bird/Y (1.8 ± 0.1, n = 7) vs their WT littermates (1.2 ± 0.1, n = 6; P < 0.05) (Fig. 6.4E1). 
However, the rectification ratio of LC neurons was not significantly different between 
Mecp2R168X/Y and Mecp2Bird/Y mice after normalization (Fig. 6.4E2). 
6.4.5 LC Neuron Excitability 
Increased LC neuronal hyperexcitability has been found in Mecp2Bird/Y mice which is 
likely to contribute to defects in the NE system in the mice [136, 137]. Therefore, we measured 
the spontaneous firing activity as well as other active membrane properties of LC cells in these 
mice. The spontaneous firing activity of LC neurons from Mecp2R168X/Y mice (6.6 ± 0.7 Hz, n = 
14) was significantly higher compared to their WT littermates (3.9 ± 0.3 Hz, n = 14; P < 0.01). 
These were similar to Mecp2Bird/Y mice (6.8 ± 0.5 Hz, n = 7) vs their WT littermates (3.4 ± 0.5 
Hz, n = 5; P < 0.01) (Fig. 6.5A-C1). After normalization to the WT values, the firing rates were 
not significantly different between Mecp2R168X/Y and Mecp2Bird/Y mice (Fig. 6.5C2).  
Spike frequency adaptation (SFA) is a response of neurons to continuing excitatory 
inputs. In the present study, the SFA was calculated as the firing frequency of the first two action 
potentials as the peak state (Fp) divided by the firing frequency of the action potentials at steady 
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state (Fs). Both Fp (34.6 ± 3.9 Hz, n = 8) and Fs (34.2 ± 2.4 Hz, n = 8) were significantly higher 
in Mecp2R168X/Y mice than in their WT littermates (24.1 ± 1.4 Hz, n = 8 and 22.2 ± 1.4 Hz, n = 8, 
respectively) (Fig. 6.5D). Similarly, LC neurons from Mecp2Bird/Y mice also showed significantly 
higher Fp and Fs than WT cells (Fig. 5E). Neither Fp nor Fs showed a significant difference 
between Mecp2Bird/Y and Mecp2R168X/Y neurons (Fig. 6.5F). SFA also was not significantly 
different between Mecp2R168X/Y, Mecp2Bird/Y mice and their WT littermates (Fig. 6.5G). 
 Afterhyperpolarization (AHP) following each action potential contributes to setting the 
firing rate of neurons. Because we observed changes in spontaneous FR, we studied AHP 
characteristics. The AHPs consisted of fast (fAHP) and slow (sAHP) components. AHP 
amplitude was measured from the AP threshold level to the lowest hyperpolarizing potential of 
the AHP. We did not find any difference in the proportions of cells with fAHP and sAHP 
between the mutant strains and their WT littermates. There was no significant difference in 
sAHP amplitude between Mecp2R168X/Y (-24.0 ± 2.2 mV, n = 8) and WT cells (-26.0 ± 2.1 mV, n 
= 8; P > 0.05) (Fig. 6.5H1). The average sAHP amplitude between Mecp2Bird/Y (-26.0 ± 1.4 mV, n 
= 8) also was not significantly different compared to WT cells (-26.0 ± 1.6 mV, n = 6; P > 0.05) 
(Fig. 6.5H1). After normalization, Mecp2R168X/Y (0.9 ± 0.1, n = 8) and Mecp2Bird/Y (1.0 ± 0.1, n = 
8; P > 0.05) were not significantly different (Fig. 6.5H2). We also compared the sAHP area and 
found no significant difference between Mecp2R168X/Y (1731.2 ± 395.1 mV×ms, n = 8) and WT 
cells (1976.9 ± 248.9 mV×ms, n = 8; P > 0.05) (Fig. 6.5I1). There was also no significant 
difference between Mecp2Bird/Y (2368.6 ± 311.3 mV×ms, n = 8) and WT cells (3179.9 ± 603.3 
mV×ms, n = 6; P > 0.05) (Fig. 6.5I1). Mecp2R168X/Y (0.9 ± 0.2, n = 8) and Mecp2Bird/Y (0.7 ± 0.1, 
n = 8; P > 0.05) were not significantly different after normalization (Fig. 6.5I2). 
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6.4.6 LC AP Characteristics 
Action potential width was visibly different in both Mecp2R168X/Y and Mecp2Bird/Y 
compared to WT cells (Fig. 6.6A,B). AP amplitude of LC neurons from Mecp2R168X/Y mice (78.0 
± 3.7 mV, n = 8) was not significantly different from that of WT mice (79.8 ± 4.6 mV, n = 8; P > 
0.05) (Fig. 6.6C1). AP amplitude of LC neurons from Mecp2Bird/Y (90.7 ± 4.7 mV, n = 8) also 
was not significantly different from their WT littermates (89.2 ± 3.9 mV, n = 6; P > 0.05). When 
AP amplitude was normalized to WT levels, there was no significant difference between 
Mecp2R168X/Y mice (1.0 ± 0.5, n = 8) and Mecp2Bird/Y mice (1.0 ± 0.1, n = 8; P > 0.05) (Fig. 
6.6C2). AP threshold (-33.3 ± 0.9 mV, n = 8; P < 0.05) was significantly lower in Mecp2R168X/Y 
mice than in their WT littermates (-29.1 ± 1.4 mV, n = 8), (Fig. 6.6D1). The threshold of 
Mecp2Bird/Y mice (-39.1 ± 0.8 mV, n = 8) was also significantly lower compared to their WT 
littermates (-33.5 ± 2.0 mV, n = 6; P < 0.05). After normalization the AP threshold of 
Mecp2R168X/Y mice (1.1 ± 0.0, n = 8) was not significantly different compared to Mecp2Bird/Y mice 
(1.2 ± 0.0, n = 8; P > 0.05) (Fig. 6.6D2).  
AP width measured at 50% AP amplitude (APD50) was significantly longer in 
Mecp2R168X/Y (1.5 ± 0.1 ms, n = 8) compared to WT cells (1.1 ± 0.1 ms, n = 8; P < 0.05) (Fig. 
6.6E). The APD50 from Mecp2Bird/Y mice (1.7 ± 0.1 ms, n = 8) was also significantly longer than 
that of WT cells (1.2 ± 0.1 ms, n = 6; P < 0.01). The rise times of Mecp2R168X/Y and Mecp2Bird/Y 
mice were significantly higher compared to their WT littermates (Fig. 6.6F). Though decay times 
were slightly higher in Mecp2R168X/Y and Mecp2Bird/Y mice compared to their WT littermates, 
they were not significantly different (Fig. 6.6G). After normalizing to the WT values, there was 
no significant difference between Mecp2R168X/Y and Mecp2Bird/Y mice in APD50, rise time, and 
decay time (Fig. 6.6H). 
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6.4.7 LC Delayed Excitation 
Delayed excitation (DE) is a characteristic property of LC neurons, which is described as 
a delayed occurrence of action potentials following hyperpolarization. This property, like IR, 
also affects how LC cells respond to inhibitory and excitatory input, further affecting their firing 
activity. DE was analyzed by fitting the time delay of the first action potential with the 
Boltzmann equation D = 1 /{1 + exp [− (V − V½) / k]} where D is the delay period, V is the 
hyperpolarizing membrane potential, V½ is the half-inactivation, and k is the slope factor. All 
cells showed typical delayed excitation (Fig. 6.7A,B). The V1/2 of LC cells from Mecp2R168X/Y 
mice was slightly more hyperpolarized than that of WT cells, but was not significantly different 
(-70.2 ± 1.2 mV, n = 8, Mecp2R168X/Y, -66.5 ± 3.6 mV, n = 8 , WT; P > 0.05) (Fig. 6.7C, E1). The 
V1/2 of Mecp2Bird/Y cells was not significantly different from WT cells (-63.2 ± 3.1 mV, n = 8, 
Mecp2Bird/Y, -64.9 ± 4.9 mV, n = 6, WT; P > 0.05) (Fig. 6.7D, E1). Mecp2R168X/Y and Mecp2Bird/Y 
cells were not significantly different after normalization (Fig. 6.7E2). The slope factor also was 
not significantly different in Mecp2R168X/Y cells (5.6 ± 0.6, n = 8, Mecp2R168X/Y, 7.1 ± 0.9, n = 8, 
WT; P > 0.05) or Mecp2Bird/Y cells (6.8 ± 1.3, n = 8, Mecp2Bird/Y, 9.3 ± 1.2, n = 6, WT; P > 0.05) 
(Fig. 6.7F1). Mecp2R168X/Y and Mecp2Bird/Y were not significantly different after normalization 
(Fig. 6.7F2). 
6.4.8 Excessive Activity of Me5 Neurons 
The abnormal motor function may involve the propriosensory system in addition to the 
pyramidal and extrapyramidal systems. Indeed, we have recently shown that the Mecp2 
disruption altered membrane properties of mesencephalic trigeminal nucleus neurons (Me5) in 
Mecp2Bird/Y [196]. Hence, we studied how the Mecp2R168X/Y mutation affects the membrane 
properties in these cells. The Me5 cells are typically silent in brain slices. To test their 
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excitability we measured the average instantaneous firing rate in response to depolarizing current 
injections. Me5 neurons from Mecp2R168X/Y displayed a higher firing frequency in response to the 
same depolarizing current injections than those from WT mice (Fig. 6.8A-C1). When the 
maximal firing rate was compared at the same current injection, Me5 neurons from Mecp2R168X/Y 
mice fired significantly faster than their WT littermates (46.2 ± 16.2 Hz, n = 10 in Mecp2R168X/Y, 
5.9 ± 4.0 Hz, n = 15 in WT; P < 0.05), which were similar to Me5 cells from Mecp2Bird/Y mice 
(126.3 ± 18.4 Hz, n = 9) vs the WT (66.8 ± 20.6 Hz, n = 9; P < 0.05) (Fig. 6.8C1,C2). When the 
difference in firing rates was compared between null and WT mice, no significant difference was 
found between Mecp2R168X/Y and Mecp2Bird/Y mice (Fig. 6.8D1).  
The minimum current needed to elicit action potentials (rheobase) was not significantly 
different, in both Mecp2R168X/Y (475.0 ± 91.1 pA, n = 10, Mecp2R168X/Y, 378.7 ± 57.3 pA, n = 15, 
WT; P > 0.05) and Mecp2Bird/Y (274.3 ± 82.6 pA, n = 7, Mecp2Bird/Y, 233.8 ± 31.1 pA, n = 8, WT; 
P > 0.05) (Fig. 6.8D2). Mecp2R168X/Y mice (1.0 ± 0.5, n = 8) and Mecp2Bird/Y mice (1.0 ± 0.1, n = 
8; P > 0.05) were not significantly different after normalization (Fig. 6.8E). Me5 neurons tended 
to fire either three or fewer action potentials or multiple action potentials sustained throughout 
the current injection as previously reported [197, 198]. Both Mecp2R168X/Y (5:9, Mecp2R168X/Y ; 
1:17, WT; P < 0.05) and Mecp2Bird/Y mice (5:4, Mecp2Bird/Y; 1:8, WT; P < 0.05) had higher ratios 
of cells that fired multiple action potentials to fewer than three multiple action potentials than 
cells from WT littermates (Fig. 6.8F). 
There were no significant differences in resting membrane potentials in either 
Mecp2R168X/Y or Mecp2Bird/Y strains compared to their WT littermates (Fig. 6.8G1, G2). Also, 
neither strain showed a significant difference in membrane capacitance or input resistance 
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measured from the linear portion of the I/V plot when compared to their WT littermates (Fig. 6.8 
H1,H2).  
6.4.9 Me5 AP Characteristics 
We compared action potential (AP) characteristics as we did with LC neurons (Fig 
6.9A,B). The average AP threshold from Mecp2R168X/Y mice (-38.0 ± 2.0 mV, n = 6) was 
significantly hyperpolarized compared to their WT littermates (-29.8 ± 2.7 mV, n = 8; P < 0.05) 
(Fig. 6.9C1). The threshold of Mecp2Bird/Y mice (-37.0 ± 1.2 mV, n = 6) was also significantly 
more hyperpolarized compared to their WT littermates (-32.7 ± 1.3 mV, n = 8; P < 0.05). After 
normalization, AP threshold from Mecp2R168X/Y mice (1.3 ± 0.1, n = 6) was not different than that 
from Mecp2Bird/Y mice (1.1 ± 0.0, n = 6; P > 0.05) (Fig. 6.9C2). The average AP amplitude of 
Me5 neurons from Mecp2R168X/Y mice (59.0 ± 1.6 mV, n = 6) was not significantly different from 
that of WT mice (61.1 ± 2.2 mV, n = 8; P > 0.05) (Fig. 6.9D1). Mecp2Bird/Y mice (66.9 ± 2.3 mV, 
n = 6) and their WT littermates (66.1 ± 1.7 mV, n = 8; P > 0.05) were also not significantly 
different (Fig. 6.9D1). There was no significant difference in AP amplitude between 
Mecp2R168X/Y mice (1.0 ± 0.0, n = 6) and Mecp2Bird/Y mice (1.0 ± 0.0, n = 7; P > 0.05) after 
normalization to WT levels (Fig. 6.9D2). In addition, there were no significant differences in 
action potential overshoot of either mutant strain compared to their WT littermates. 
The APD50 was not significantly different in either Mecp2R168X/Y (0.30 ± 0.0 ms, n = 6, 
Mecp2R168X/Y, 0.38 ± 0.0 ms, n = 8, WT; P > 0.05) or Mecp2Bird/Y mice (0.35 ± 0.0 ms, n = 6, 
Mecp2Bird/Y, 0.38 ± 0.0 ms, n = 8, WT; P >0.05) (Fig. 6.8E). Neither rise time nor decay time 
were significantly different in Mecp2R168X/Y and Mecp2Bird/Y mice than their WT littermates (Fig. 
6.8F, G). After normalization, APD50, rise time, and decay time from Mecp2R168X/Y cells were 
not significantly different than cells from Mecp2Bird/Y mice (Fig. 6.8H). 
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6.4.10 Neuronal Defects in Female Mice 
 To distinguish symptomatic female mice from asymptomatic female mice we 
used plethysmography as described in a previous report [199].We then compared the firing rates 
of LC cells from these mice. The average spontaneous firing rate of LC cells from symptomatic 
Mecp2R168X/− mice (sMecp2R168X/−) (5.1 ± 0.6 Hz, n = 14) was significantly higher than that of 
WT cells (3.3 ± 0.3 Hz, n = 13; P < 0.01) (Fig. 6.10 A1-B1). Cells from symptomatic Mecp2Bird/− 
mice (sMecp2Bird/−) (6.3 ± 0.8 Hz, n = 20) were also significantly higher compared to their WT 
littermates) (Fig. 6.10B1). There was no significant difference in neuronal FR between 
Mecp2R168X/Y and Mecp2Bird/Y mice after normalization (Fig. 6.10B2). We also compared AP 
threshold as in the male mice and found that AP threshold (-35.9 ± 1.3 mV, n = 7; P < 0.05) was 
significantly lower in sMecp2R168X/− mice than in aMecp2R168X/− mice (-27.4 ± 3.4 mV, n = 7; P < 
0.05; Fig. 6.10C1). The threshold of sMecp2Bird/− mice (-35.6 ± 2.4 mV, n = 7) was also 
significantly lower compared to aMecp2Bird/− mice (-26.0 ± 3.4 mV, n = 7; P < 0.05). Normalized 
AP threshold of sMecp2R168X/− mice (1.3 ± 0.0, n = 7) was not significantly different from 
sMecp2Bird/− mice (1.4 ± 0.1, n = 7; P > 0.05) after dividing AP threshold of the symptomatic 
values by the mean asymptomatic values in both strains (Fig. 6.10C2). 
When the firing rates of evoked APs were compared in the Me5 cells, we saw a similar 
trend as in male mice, i.e., the ceiling-level firing rate in sMecp2R168X/− (80.4 ± 23.1 Hz, n = 11) 
was significantly higher than in aMecp2R168X/− cells (23.1 ± 15.1 Hz, n = 12; P < 0.05). The 
average evoked FR was also significantly higher in sMecp2Bird/− (139.5 ± 36.6 Hz, n = 13) 
compared to aMecp2Bird/− mice (63.3 ± 31.0 Hz, n = 11; P < 0.01) (Fig. 6.10D1). After 
normalization, there was no significant difference between sMecp2R168X/− (57.3 ± 23.1 Hz, n = 
11) and sMecp2Bird/− (76.1 ± 36.6 Hz, n = 13; P > 0.05) (Fig. 6.10D2). Also similar to male mice, 
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the AP threshold from sMecp2R168X/− mice (-35.7 ± 0.8 mV, n = 8) was significantly 
hyperpolarizing compared to aMecp2R168X/− (-32.8 ± 0.7 mV, n = 9; P < 0.05) (Fig. 6.10E1). The 
threshold of sMecp2Bird/− mice (-29.1 ± 2.0 mV, n = 7) was also significantly more 
hyperpolarized compared to aMecp2Bird/− mice (-24.2 ± 0.9 mV, n = 8; P < 0.05). After 
normalization, AP threshold from sMecp2R168X/− mice (1.1 ± 0.0, n = 8) was not significantly 
different from aMecp2Bird/− mice (1.2 ± 0.1, n = 7; P > 0.05) (Fig. 6.10E2).  
6.5 Discussion 
This is the first demonstration of cellular properties in the Mecp2R168X/Y mouse model. 
Our results have shown that breathing and motor function are clearly impaired in the 
Mecp2R168X/Y mice. Our further studies of the intrinsic membrane properties of brainstem 
neurons indicate defects in LC neurons and Me5 neurons, which are known to play a role in 
breathing regulation and motor controls, respectively.  
6.5.1 The R168X Mutation 
In the R168X mutant, a point mutation causes a replacement of an arginine to a stop 
codon at residue 168, leading to premature termination of the MeCP2 peptide chain. This 
mutation occurs in approximately 8-12% of RTT patients making it one of the most common 
causes for MeCP2 disruptions, alongside the T158A/M mutations [187]. With the Mecp2R168X/Y 
mutation, the truncated MeCP2 protein loses the transcription repressor domain, though its 
methyl binding domain seems to remain [186]. As a result, the MeCP2 protein can no longer 
function as a transcriptional factor, though it still can bind to DNA.  
Several studies indicate that mutations closer to the N terminal are associated with higher 
severities of symptoms than those closer to the C terminal [35, 200]. In human patients with the 
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Mecp2R168X/Y mutation demonstrated a high severity of motor dysfunction close to those with a 
large deletion, similar to the Mecp2Bird/Y mouse model [35, 201]. 
Recently another Mecp2R168X/Y mouse model has been created [168, 202]. The authors 
reported that their males showed similar phenotypes to the original Mecp2R168X/Y mouse model. 
Similarly, by comparing the results of our study which used the original Mecp2R168X/Y mouse 
model with the published results from the new model, we also did not find any obvious 
phenotypic differences between these two Mecp2R168X/Y mouse models. The female mice from 
the original model, though, showed a reduced body weight whereas the mice from the new 
model did not [188]. In addition, no breathing abnormalities were observed in the females of the 
new Mecp2R168X model, whereas they were found in some females of the original Mecp2R168X 
model. Because similar minor phenotypical variations have been reported by different research 
groups in the Mecp2Bird/Y model, the phenotypic differences between the original and new 
Mecp2R168X models appear modest. 
6.5.2 Behavioral and functional findings from R168X mice 
In our present study, we have compared the behavioral and cellular phenotypes between 
Mecp2R168X/Y and Mecp2Bird/Y mice. Both strains show lower body weight compared to their WT-
littermates. Although this is consistent with most previous studies, subsets of male Mecp2R168X/Y 
and Mecp2Bird/Y mice showed body weight similar to and larger than the WT in some studies [46, 
52]. Interestingly, the Mecp2R168X/Y mice are smaller than the Mecp2Bird/Y mice under the same 
housing condition as shown in this study. This seems to be due to the difference in their genetic 
background as previously reported [102]. The Mecp2R168X/Y mice were originally generated on a 
mixed genetic background of C57BL/6J x 129S6/SvEvTac, while Mecp2Bird/Y mice were created 
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on a pure C57BL/6 background. The Mecp2R168X/Y mice also showed reduced lifespan and 
stereotypical hindlimb clasping, both of which are similar to Mecp2Bird/Y mice [46, 52].  
Motor dysfunction is a RTT-like phenotype. We have compared the grip strength 
between these two strains in this study, and found that grip strength is significantly lower than 
that in their WT littermates. There is no significant difference between the two mutant strains in 
the grip strength, which indicates that muscle tone is similarly impaired in both mutant strains. 
Motor coordination is defective in Mecp2R168X/Y mice as shown in the grid walking test. When 
the motor coordination was compared between the two mutant strains, both showed impairments 
to a similar degree. These observations are thus consistent with previous studies, and suggest 
impairment in motor coordination in both mutant strains. 
Breathing dysfunction is a characteristic of RTT seen in human patients and mouse 
models [94, 203]. Among the potential causes for the increased incidence of breathing 
irregularities and apneas are the defective CO2 sensing mechanisms in RTT patients and 
obstruction of the upper airways [94, 97, 204]. Our study presents, for the first time, quantitative 
analysis of breathing abnormalities in male Mecp2R168X/Y mice, including breathing frequency 
variation and apneas. These are consistent with breathing abnormalities of Mecp2Bird/Y shown in 
this study as well as previous reports [82, 94, 181]. No significant differences were found in 
breathing frequency variation and apnea counts between Mecp2Bird/Y and Mecp2R168X/Y mice, 
suggesting that both types of Mecp2 disruptions causes defects in these breathing parameters to a 
similar degree.  
Overall, the behavioral phenotypes between Mecp2R168X/Y and Mecp2Bird/Y mice were 
indistinguishable in our study. In one previous study characterizing this mouse model, the 
authors compared their results to Mecp2Jae/Y mice, another RTT mouse model which has an exon 
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3 deletion [188]. The authors compared the onset of symptoms in the Mecp2R168X/Y model to that 
of Mecp2Jae/Y mice and concluded that there was no difference in males. Female Mecp2R168X/X 
mice did show a subtle difference in increased anxiety at a later age.  
6.5.3 Defects in brainstem neuronal activity 
The locus coeruleus is the major provider of NE in the CNS affecting many systems and 
functions. In these RTT mouse models, LC neurons show increased spontaneous firing activity 
as well as other alterations in their membrane properties. We have previously found that the 
hyperexcitability of LC neurons in Mecp2Bird/Y mice can be attributed to changes in intrinsic 
membrane properties and alterations of different ion channel expression [137]. In addition to 
these changes in intrinsic membrane properties, the inhibitory GABA input to LC cells is 
reduced, further enhancing LC neuronal excitability [147]. In our current study, we saw similar 
changes in LC properties including hyperexcitability in Mecp2R168X/Y mice as in Mecp2Bird/Y 
mice. Because behavioral phenotypes are very similar between the two strains, the finding that 
their neuronal activities are similarly affected is not surprising. 
As the major provider of NE in the CNS, proper LC cell function is crucial for 
maintaining normal function and behaviors. In human RTT patients and RTT mouse models the 
amount of available NE in the CNS is reduced [75, 79]. This has been attributed to impaired NE 
synthesis [193]. Raising the amount of available NE at synapses with the NE reuptake blocker 
desipramine improves symptoms such as breathing dysfunction and increases the lifespan of 
mouse models further supporting its role in the development of symptoms in this disease [86, 
87]. Alternatively, increasing the firing rate of LC cells could also lead to more NE release from 
LC neuronal synaptic terminals, which might alleviate RTT-like symptoms as well.  
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However, our recent study using optogenetic interventions indicates that the increased 
firing rate of LC cells does not improve NE release from Mecp2-null neurons at all [205]. 
Therefore, LC neuronal hyperexcitability does not seem beneficial to the NE modulation, and 
may actually impair NE synthesis due to the increased energy consumption and intracellular Ca++ 
overload [205]. In fact, several studies have shown that reducing neuronal excitability by 
enhancing inhibitory signaling in RTT mouse models benefits RTT-like symptom reliefs [82, 
171, 172].  
Motor dysfunction is a prominent symptom of RTT patients. Among other motor 
functions, RTT patients exhibit dysfunction in facial movements such as chewing and teeth 
grinding [206]. Consistent with findings in humans, we have observed misalignment of the jaw 
and teeth overgrowth in Mecp2R168X/Y mice which has also been reported in Mecp2Bird/Y mice as 
well [46]. The Me5 contains propriosensory neurons that act as a feedback mechanism for jaw 
and facial muscles. Because of their ideal anatomical position, the location of Me5 neurons 
provides an opportunity to study the propriosensory component of the motor system. We have 
previously found that Me5 neurons in Mecp2Bird/Y mice display excessive firing activity as LC 
cells [196]. The increased firing activity of Me5 neurons seems to be attributed to reorganization 
of INa and Ih [196]. In our current study of Mecp2R168X/Y mice, we have also found 
hyperexcitability of Me5 neurons that was comparable to the hyperexcitability found in Me5 
neurons from Mecp2Bird/Y mice. This hyperexcitation of propriosensory neurons may cause 
abnormal feedback to motor neurons, causing more excitation of jaw muscles, and thus 
exacerbating the defects in the motor system. 
In conclusion, we have compared several behavioral and cellular outcomes between two 
strains of RTT mouse models. LC neurons in both mutant strains show defects in their intrinsic 
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membrane properties leading to excessive firing activity. Consistent with these defects are 
breathing abnormalities seen in both mutant strains. The Me5 neurons in both strains of RTT 
models display higher firing responses to depolarization than their WT littermates. These 
neurons are propriosensory, regulating motor neurons via certain servo feedback circuits. Their 
dysfunction thus is consistent with the motor defects in muscle strength and coordination. Both 
LC and Me5 neurons with hyperexcitability should have an impact on the excitation-inhibition 
balances in brainstem neuronal networks as well as their associated functions. Interventions 
targeted towards reducing hyperexcitability in the CNS should help correct this excitation-
inhibition imbalance. A MeCP2 protein product was previously detected in the original 
Mecp2R168X/Y mouse model [52] and in several in-vitro assays in HeLA cells, Xenopus, and yeast 
cells, indicating that a stable truncated protein can be expressed [207-209]. In contrast, no 
protein product was detected in the new Mecp2R168X/Y mouse model and in an in-vitro assay 
[168, 186]. Though this study did not test for protein expression, based on our results the 
truncation does not seem to have evident effects on the behavioral and cellular manifestations in 
the mice, suggesting that the transcriptional repressor domain of the protein is indeed necessary 
for proper functioning of the CNS in RTT patients, whereas the methyl binding domain alone has 
little effects. In addition, the comparability in phenotypical outcomes of the Mecp2R168X/Y model 






Figure 6.1 General Abnormalities of Mecp2R168X/Y Mice.  
A. Photographs of a male Mecp2R168X/Y (R168X) mouse and its wild-type (WT) littermate at five weeks of age. The 
R168X mouse displayed hindlimb clasping, and the WT littermate did not. B. Male R168X mouse was smaller than 
to its WT littermate. C1. Both R168X and Mecp2Bird/Y (Bird) mice had lower body weight compared to their WT 
littermates. C2. Bird mice weighed significantly higher than R168X mice after normalization to the average body 
weight of WT littermates. D. The survival curves of R168X and WT were normalized to 100% with the 50% death 
rate indicated by the vertical line. E. The survival curves of Bird and WT were normalized to 100% with the 50% 
death rate indicated by the vertical line. (** P<0.01, *** P<0.001; two-tail Student’s t-test). Data are presented as 






Figure 6.2 Breathing Abnormalities. 
A1- B2. Traces of breathing activity from male Mecp2R168X/Y (R168X), Mecp2Bird (Bird) and wild-type (WT) mice. 
R168X and Bird mice displayed periods of slow and fast breathing as well as apneas, while the WT mice did not. 
C1. Breath frequency (f) variation was significantly higher in R168X mice than in their WT littermates, as was 
found in Bird mice. C2. There was no significant difference in f variation between R168X and Mecp2Bird/Y (Bird) 
mice after normalization to their WT littermate levels. D1. Apnea counts shown as Apneas / h were significantly 
higher in both R168X and Bird mice compared to their WT littermates. D2. No significant difference in apnea counts 






Figure 6.3 Reduced Motor Function. 
A1. Mecp2R168X/Y (R168X) mice displayed lower grip strength compared to their WT littermates. So did Mecp2Bird/Y 
(Bird) mice. A2. The grip strength of R168X mice were not significantly different from Bird mice after 
normalization to wild-type (WT) levels. B1. In comparison to WT mice, both R168X and Bird mice displayed a 
higher percentage of foot faults in the grid walking test. B2. After normalization, foot faults between R168X and 
Bird mice were not significantly different from each other. *, P<0.05; **, P<0.01; ***, P<0.001; NS, P>0.05; two-





Figure 6.4 Altered Passive Membrane Properties of LC Neurons. 
A1, A2. Whole-cell current clamp recordings from R168X and WT LC neurons (upper trace) with steps of 
hyperpolarizing current injections (lower trace). B. I-V plots of the LC neurons in A1 and A2 which show inward 
rectification. C1. LC cells from R168X mice displayed a more depolarizing membrane potential (Vm) than the WT 
cells, which was also seen in LC cells from Bird mice. C2. There was no significant difference in resting membrane 
potential between R168X and Bird mice after normalization to WT levels. D1, D2. Input resistance (Rm) was not 
significantly different in R168X and Bird mice compared to input resistance in WT mice before and after 
normalization to WT levels. E1. Inward rectification (IR) ratio was measured as the input resistance at −70 mV 
divided by that at −100 mV, which was significantly higher in R168X and Bird mice than their WT littermates. E2. 
There was no significant difference in IR ratio between the two strains of mutant mice after normalization to WT 




Figure 6.5 Active Membrane Properties of LC Neurons. 
A,B. Recordings from spontaneously firing LC neurons in WT and R168X mice shown in the same time and 
amplification scales. C1. The spontaneous firing rate (FR) of LC cells from both strains of mutant mice was 
significantly higher than their WT littermates. C2. Normalized spontaneous FR was not significantly different 
between R168X and Bird mice. D,E. Both peak frequency (Fp) and steady state frequency (Fs) were higher in 
R168X and Bird mice than WT cells. F. Normalized Fp and Fs were not significantly different between R168X and 
Bird mice. G. Spike frequency adaptation (SFA) was calculated as Fp/Fs. Compared to WT cells, neither R168X nor 
Bird cells showed a significant difference. H1. The average amplitudes of sAHP of R168X and Bird cells were not 
significantly different from WT cells. H2. Normalized sAHP amplitude was not significantly different between 
R168X and Bird mice. I1. The average sAHP area of R168X and Bird cells were not significantly different from WT 
cells. I1. Normalized sAHP area was not significantly different between R168X and Bird mice. *, P<0.05; **, 






Figure 6.6 LC Neuron Action Potential Morphology. 
A, B. Representative action potentials (AP) from R168X, Bird, and WT littermate cells. C1. Action potential 
amplitudes were not significantly different between either R168X and WT cells or Bird and WT cells. C2. 
Normalized to WT levels, there was no significant difference between R168X and Bird cells. D1. AP threshold was 
significantly different between R168X and WT cells, and between Bird and WT. D2. AP threshold of R168X and 
Bird mice were not significantly different after normalization. E,F. Both the AP half duration (APD50) and rise time 
were significantly different when R168X and Bird cells were compared to their WT littermates. G. The decay times 
of R168X and Bird mice were not significantly different from WT cells. H. After normalization, there were no 




Figure 6.7 Delayed Excitation in LC Neurons. 
A,B. Whole-cell current clamp recordings of LC neurons from R168X and WT mice, respectively. With a series of 
hyperpolarizing steps followed by a depolarizing pulse the neurons showed delayed excitation (DE). Arrows 
indicate the delay of the first spike which increased with increasing hyperpolarizing steps. C,D. The relationship 
between action potential delays and the membrane potentials was fitted with the Boltzmann equations in 
representative R168X, Bird and WT neurons. E1. There was no difference in the V½ between R168X, Bird, and WT 
cells. E2. After normalization, there was no significant difference between R168X and Bird cells. F1. Slope factors 
between R168X and WT mice were not significantly different. F2. There was no difference between R168X and 






Figure 6.8 Altered Membrane Properties of Me5 Neurons. 
A,B. Depolarizing current injections elicited action potentials in Me5 cells from R168X and WT mice, respectively. 
C1.  The average instantaneous firing rate (FR) of action potentials at increasing step current injections was 
compared between R168X and WT cells. C2. The FR at the same current injections were higher in R168X and Bird 
cells than in cells from their WT littermates. D1. Changes in FR were compared by subtracting the WT mean value 
in each strain. The FR changes were not significantly different between R168X and Bird cells, although Bird cells 
tended to firing more action potentials overall. D2. The rheobases of R168X and Bird cells were not significantly 
different compared to WT cells. E. There was no difference between R168X and Bird cells after normalization. F. 
The ratio of cells that fired few action potentials vs multiple action potentials were significantly different compared 
to WT cells in R168X and Bird cells. G1, G2. The average resting membrane potentials (Vm) of R168X and Bird 
cells were not significantly different compared to WT cells, or from each other. H1. The input resistance (Rm) of 
R168X and Bird cells were not significantly different from WT cells. H2. After normalizing to WT cells, the input 









Figure 6.9 Me5 Neuron Action Potential Morphology. 
A, B. Representative action potentials (AP) from R168X, Bird, and WT littermate cells. C1. Action potential 
thresholds were significantly different between when R168X and Bird cells were compared to their WT littermates. 
C2. R168X cells were not significantly higher than Bird cells after normalization. D1. Neither R168X nor Bird AP 
amplitudes were different than cells from WT littermates. D2. R168X and Bird mice were not significantly different 
after normalization. E-G. The AP half durations (APD50), rise times, and decay times not were significantly 
different when R168X and Bird cells were compared to their WT littermates. H. After normalization, there were no 




Figure 6.10 Firing properties of cells from female Rett mouse models. 
A1-B1. The spontaneous firing activity of LC cells from asymptomatic Mecp2R168X/+ (aR168X), symptomatic 
Mecp2R168X/+ (sR168X), asymptomatic Mecp2Bird/+ (aBird), and symptomatic Mecp2Bird/+ (sBird) mice were 
compared. Both sR168X and sBird cells fired at a significantly higher rate than their asymptomatic littermates. B2. 
There was no significant difference after normalization between sR168X and sBird cells. C1. LC action potential 
thresholds were significantly lower in sR168X and sBird cells compared to aR168X and aBird cells. C2. LC Action 
potential thresholds of sR168X and sBird mice were not significantly different after normalization. D1. As in males, 
the firing rate at the same current injection from Me5 neurons were compared in female mice. The evoked FR in 
both sR168X and sBird mice were significantly higher than their asymptomatic littermates. D2. After normalization, 
there was no significant difference between sR168X and sBird mice. E1. Me5 action potential thresholds were 
significantly lower in both sR168X and sBird cells compared to aR168X and aBird cells. E2. sR168X cells were not 
significantly different from sBird cells after normalization.  
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7 RESULT 3: The antitussive cloperastine improves breathing abnormalities in a Rett 
Syndrome mouse model by blocking presynaptic GIRK channels and enhancing 
GABA release.  
These studies have led to a manuscript submitted for publication. 
Authors: Christopher M. Johnson, Ningren Cui, Hao Xing, Yang Wu, Chun Jiang.  
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7.2 Abstract 
Rett Syndrome (RTT) is an X-linked neurodevelopmental disorder caused mainly by 
mutations in the MECP2 gene. One of the major RTT features is breathing dysfunction 
characterized by periodic hypo- and hyperventilation. The breathing disorders are associated 
with increased brainstem neuronal excitability, which can be alleviated with antagonistic agents. 
Since neuronal hypoexcitability occurs in forebrain of RTT models, it is necessary to find 
pharmacological agents with a relative preference to brainstem neurons. Here we show evidence 
for the improvement of breathing disorders of Mecp2-null mice with the brainstem-acting drug 
cloperastine (CPS) and its likely neuronal targets. CPS is an over-the-counter cough medicine 
that has an inhibitory effect on brainstem neuronal networks. In Mecp2-null mice, CPS (30 
mg/kg, i.p.) decreased the occurrence of apneas/h and breath frequency variation. GIRK currents 
expressed in HEK cells were inhibited by CPS with IC50 1 μM. Whole-cell patch clamp 
recordings in locus coeruleus (LC) and dorsal tegmental nucleus (DTN) neurons revealed an 
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overall inhibitory effect of CPS (10 μM) on neuronal firing activity. Such an effect was reversed 
by the GABAA receptor antagonist bicuculline (20 μM). Voltage clamp studies showed that CPS 
increased GABAergic sIPSCs in LC cells, which was blocked by the GABAB receptor antagonist 
phaclofen. Functional GABAergic connections of DTN neurons with LC cells were shown. 
These results suggest that CPS improves breathing dysfunction in Mecp2-null mice by blocking 
GIRK channels in synaptic terminals and enhancing GABA release.  
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7.3 Introduction   
Rett Syndrome (RTT) is an X-linked neurodevelopmental disorder seen in 1 in 10,000 
females. Most cases of RTT are caused by mutations in the MECP2 gene encoding Methyl-CpG-
binding protein 2. People with RTT show periodic hypoventilation attacks that contribute to the 
high incidence of sudden death. Although the RTT-characteristic hypoventilation is known to 
originate from the central nervous system (CNS), the underlying cellular mechanisms are still 
unclear [210]. Several potential defects have been suggested, including impaired higher brain 
control, abnormal CO2 chemoreception, and inadequate termination of inspiratory phase [60, 78, 
94, 211]. A common event of these defects is the disruption in neuronal communication, which is 
likely to play a major role in RTT-type breathing disorders. Indeed, several neurotransmitter 
systems have been reported to be impaired in people with the disease as well as animal models, 
including norepinephrine (NE), serotonin (5-HT), GABA and glutamate [9, 10, 75, 132, 191, 
212]. Consistent with these findings, manipulations of these neurotransmitters have been shown 
to be beneficial for the symptom [213]. 
An important consequence of the defects in these neurotransmitter systems is the shift in 
the excitation and inhibition balance that may play a role in the manifestation and development 
of RTT symptoms [131, 135]. Neuronal hyperexcitability is caused by both dysfunctions in 
neuronal networks [131-133, 214, 215] and intrinsic properties of neurons [136, 137, 216]. 
Although hypoexcitability is seen in some regions of the brain [135, 217] increased neuronal 
hyperexcitability, especially in the brainstem, is considered to be a significant contributor to the 
disease [136, 218]. In fact, drugs reducing neuronal hyperexcitability have been proven effective 
in treating RTT symptoms [82, 145, 171, 172, 214].  
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Breathing activity is controlled by the brainstem that generates rhythmic breathing and 
regulates it by integration of multiple sensory inputs from the lung and airways. Such a 
specialized brainstem function has been a major focus of pharmacological approaches for a 
number of respiration-related diseases. Several therapeutical agents are currently available that 
act on the brainstem neuronal networks with relative specificity. Some of them may be useful in 
the studies of cellular mechanisms for the RTT-type breathing, and helpful for treatment of the 
RTT hypoventilation. 
Cloperastine (CPS) is a central-acting antitussive working on brainstem neuronal 
networks [219]. The drug has several characteristics. 1) It affects the brainstem integration of 
multiple sensory inputs via multiple sites including K+ channels, histamine and sigma receptors. 
2) Its overall effect is inhibitory, suppressing cough and reactive airway signals. 3) With a large 
safety margin, it has been approved as an over-the-counter medicine in several Asian and 
European countries. 4) As a non-opioid antitussive, CPS has a potency nearly twice as high as 
codeine [220, 221]. These suggest that CPS may be of potential benefit to the understanding and 
treatment of RTT-type breathing disorders. To test this hypothesis, we performed these studies 
addressing whether CPS has effects on respiratory abnormalities in Mecp2 mutant mice, and if so 
what are the underlying cellular mechanisms. 
7.4 Results 
7.4.1 CPS Inhibited GIRK1-GIRK2 Channels Expressed Heterologically in HEK-293 Cells. 
Previous reports suggest that CPS inhibits GIRK channels [220-222]. However, its 
potency still remains unknown. Thus, we overexpressed the heteromeric GIRK1-GIRK2, the 
common isoforms of GIRK channels in the CNS, in HEK cells followed by studying GIRK 
currents in whole cell voltage clamp as we did previously [176, 177]. In the transfected cells with 
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positive GFP expression, inward rectifier currents were recorded with ramp command potentials 
from −100 to 100 mV (Fig 7.1A, B). These currents were strongly inhibited by CPS in a dose 
dependent manner with the concentration for 50% current inhibition (IC50) of approximately 1 
μM (n=12 cells) (Fig. 7.1A, C). Similar current inhibition was seen in HEK cells transfected with 
GIRK1-GIRK4 (n=11) (Fig. 7.9). 
7.4.2 CPS Decreased Apnea and Breathing Irregularity in Mecp2-Null Mice. 
The capability of CPS to suppress cough suggests that it works on brainstem neuronal 
networks that have been known to work abnormally in RTT. Thus, we tested the effectiveness of 
CPS in improving respiratory symptoms in Mecp2-null mice. Breathing activity was studied in 
Mecp2-null mice using plethysmography before and after a peritoneal injection of saline or 30 
mg/kg CPS. The Mecp2-null mice exhibited breathing abnormalities characterized by frequent 
apneas and breathing frequency variation (f variation) (Fig. 7.2A). Both were suppressed after 
CPS injection. Quantitative analysis of apnea counts as apneas/h and f variation as standard 
deviation of breathing activity divided by arithmetic mean indicated that significant reductions of 
both occurred 30 minutes after CPS injection, and the effects lasted up to 4 hours (significant 
interaction between time and treatment on apneas/h, F(3,60) = 4.05, P = 0.01 and significant 
interaction between time and treatment on f variation, F(3,60) = 7.69, P < 0.001). These changes 
were not seen in the saline group (Saline, n=9; CPS, n=13) (Fig. 7.2B-F). 
7.4.3 CPS Suppressed LC Excitability by Presynaptic Mechanisms. 
One group of cells that modulate central respiratory activity in the brainstem neuronal 
networks is the locus coeruleus (LC), which plays an important role in central CO2 
chemosensitivity and norepinephrineric modulation [223, 224]. Hyperexcitability has been 
demonstrated in these neurons in Mecp2-null mice, which likely contributes to breathing 
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abnormalities in the mice [75, 86, 87]. Thus, we studied how CPS affects the LC neurons in the 
experiments. 
LC neuronal activity was studied in whole-cell current clamp in brain slices. With step 
depolarizing current injections, firing activity was measured together with membrane potentials 
in the LC neurons. In the presence of CPS, the firing activity was significantly reduced without 
obvious changes in membrane potentials in 12 cells from WT mice (significant main effect of 
treatment, F(1,11) = 18.58, P = 0.001 and group × current injection interaction: F(3.06,33.69) = 16.865, 
P < 0.001 ; two‐way repeated measures ANOVA) (Fig 7.3A-C). This result suggests that CPS 
has effects on respiration-related brainstem neuronal networks. 
Such an effect does not seem to be a result of inhibition of somata GIRK channels in the 
LC cells alone, because GIRK channel inhibition leads to depolarization and an increase in 
neuronal excitability, which suggests that the decreased firing activity with CPS may be 
mediated by presynaptic inhibitory neurons. To test this possibility, we recorded from the LC 
neurons in the presence of the GABAA receptor blocker bicuculline. Under this condition, the 
inhibitory effect of CPS was abolished. Instead, CPS increased firing activity of LC neurons, 
which appears to be due to inhibition of postsynaptic GIRK channels (significant main effect of 
treatment, F(1,5) = 24.98, P < 0.01 and treatment × current injection interaction: F(1.71,8.55) = 5.06, 
P < 0.05 ; two‐way repeated measures ANOVA) (n=6) (Fig. 7.3D). The effects of CPS on LC 
neuronal excitability is likely to be mediated by modulation of GIRK channels, as CPS failed to 
produce any significant changes in firing activity in the presence of 300 µM BaCl2 (F(1,11) = 
0.149) (n=12) (Fig. 7.10). These results suggest that CPS inhibits GIRK channels by both pre- 
and postsynaptic mechanisms, while the former appears more prominent. 
90 
7.4.4 CPS augmented GABA synaptic drive to LC Cells. 
The elimination of the inhibitory effect of CPS with bicuculline indicates that the 
presynaptic cells are GABAergic. Thus, we studied how CPS affected GABAA IPSCs in LC 
neurons. In voltage clamp, CPS significantly increased GABAergic IPSC frequency with no 
significant effect on IPSC amplitude (n=23) (Fig. 7.4A-E). The IPSCs are GABAA receptor-
dependent as they were totally suppressed with bicuculline (Fig. 7.11). 
In addition to GABAA receptors, GABAB receptors also play a role in regulating 
excitability of postsynaptic cells through the feedback control of GABA release on presynaptic 
terminals. Using phaclofen, a selective GABAB receptor antagonist, to block GABAB receptor-
dependent feedback control, we found that CPS no longer augmented GABAergic IPSCs (n=10) 
(Fig. 7.12A-D). Therefore, it is very likely that CPS enhanced GABA transmission by blocking 
GIRK channels in the synaptic terminals including those coupled to GABAB receptors. 
7.4.5 GABAergic neurons in the DTN Projected to LC. 
A large group of GABAergic neurons, the dorsal tegmental nucleus (DTN), is located in 
close vicinity of the LC [225, 226], which largely remained in our coronal brainstem slice 
preparations, and may function to inhibit LC neurons in the slices. To demonstrate such a 
network connection, we firstly generated a strain of transgenic mice with Channelrhodopsin 
(ChR) expression in GABAergic cells using GAD-Cre and ChR-flox systems. Secondly, DTN 
neuronal responses to optostimulation were studied in whole-cell voltage clamp. We found that 
light pulses evoked a large inward current with the reversal potential near 0 mV (n=13) (Fig. 
7.5B), indicating that the current is produced by activation of ChR. When the DTN cells were 
patched randomly without verification of their GFP expression, we found that 93% of DTN cells 
showed the opto-current indicating that the nucleus is highly homogenous (n=65).  
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After confirming ChR expression in DTN cells, we recorded field potentials in the LC 
nucleus while stimulating the DTN nucleus. The blue light stimulation to the ipsilateral DTN 
evoked field potentials in the LC (n=13, Fig. 7.5 C1). Latency between onset of light and field 
potentials for 2 ms pulses was 4.0 ms (Fig. 5C2). The effect was dose-dependent as well, as 
longer pulses (5 ms) produced larger responses (n=12) (Fig. 7.5C3). Because it takes at least 2 ms 
for neurons to initiate an activation potential with optostimulation [227], these results indicate 
that DTN neurons have monosynaptic connections to LC neurons. The LC also responded to 
contralateral optostimulation with much smaller field potentials than ipsilateral stimulation (Sup 
Fig. 5A). The opto-responses in the LC were specific, which were not seen in the ventrolateral 
reticular formation in the same slices (Fig. 7.13B).  
7.4.6 CPS enhanced presynaptic GABAergic inhibition to DTN neurons  
The projection of DTN GABAergic neurons to the LC strongly suggests that these 
GABAergic neurons contribute to the synaptic modulation of LC neurons, which may be 
affected by CPS. To test this scenario, we tested how CPS affects the excitability of these 
GABAergic cells. In whole-cell current clamp with step depolarizing currents before and during 
CPS administration, we found that CPS decreased excitability of DTN cells (F(1,9) = 11.8, P < 
0.01; two‐way repeated measures ANOVA) (n=10) (Fig. 7.6A-D).  
Because CPS acts on both GIRK channels in the soma and synaptic terminals (see 
above), the mechanisms causing the DTN neuronal inhibition may be similar to those seen in LC 
neurons. If that is true, there should be previously unidentified recurrent inhibition in the DTN 
cells. We found that optostimulation also produced outward currents resembling IPSCs in some 
DTN cells (Fig. 7.7A-C). With a series of command potentials, these IPSCs reversed polarity in 
hyperpolarizing potentials, and a reversal potential occurred around -60 mV to -70 mV (Fig. 
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7.7A), which is consistent with Cl- reversal potential and indicates that the DTN GABAergic 
neurons also receive GABAergic inhibition. Thus, it appears that CPS inhibits GIRK channels 
coupled to GABAB receptors in the DTN cells, which may augment GABA release from the 
presynaptic terminals enhancing GABAergic inhibition to the DTN cells themselves as well.  
With the evidence that DTN cells receive GABAergic recurrent inhibition, we tested 
whether the inhibitory effect of CPS was caused by enhanced GABAergic transmission. Thus, 
we recorded the evoked firing activity of DTN cells before and during bath application of CPS in 
the presence of 20 μM bicuculline. Under this condition, CPS failed to decrease the excitability 
of DTN neurons (F(1,9) = 0.41, P > 0.05; two‐way repeated measures ANOVA) (n=9) (Fig. 7.8), 
indicating that the inhibitory effect relies on GABAA synaptic input. 
7.5 Discussion 
This is the first demonstration of the use of a GIRK channel blocker to improve 
respiratory symptoms in an animal model of Rett Syndrome. We have found that a single dose of 
CPS decreases the occurrence of apnea and suppresses breathing frequency variation in RTT 
mice up to four hours. This effect seems to be mediated by blocking GIRK channels in synaptic 
terminals and enhancing GABA release, as seen in multiple brain areas including the LC and the 
DTN.  
7.5.1 CPS and GIRK 
According to previous studies, CPS has GIRK channel antagonistic properties [221, 222], 
which was based on abstracts showing that CPS increases 5-HT and dopamine levels in rats 
[228, 229]. In addition, another abstract reported that IC50 for GIRK1-2 was 5-25 µM [230]. 
These concentrations are higher than the IC50 of 1 μM that we showed in this study. CPS was 
first discovered in 1961 by Takagi et al. [231] as a derivative of the antihistamine 
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diphenhydramine, and like diphenhydramine, CPS has an antitussive effect. Subsequent studies 
confirmed CPS binding to histamine receptors [219] as well as sigma receptors, [219], inhibition 
of hERG channels [232], and suppression of sodium-dependent glucose transporters [233]. Our 
current studies support that CPS also acts as a potent inhibitor of GIRK channels. 
7.5.2 GIRK Channels and Breathing 
Previous studies indicate that GIRK channels are involved in breathing regulation in WT 
animals. Activation of opioid receptors and GIRK channels in the pre-Bötzinger complex (PBC) 
as well as the Kölliker-Fuse (KF) depress respiration in mice [234, 235]. However, in GIRK2 
knockout mice, the opioid receptor and GIRK channel agonists have only a modest or no effect 
on respiratory rate [234]. Interestingly, administration of fentanyl to WT mice induced apneas 
similar to the natural occurrence of apneas in Mecp2-null mice, which is less severe in GIRK2 
knockout mice [234]. These results suggest that GIRK channels contribute to the regulation of 
respiratory-related neuronal activity and the maintenance of respiratory rhythms.  
7.5.3 Treatment of Breathing Abnormalities 
Periodic hypoventilation with apneas and breathing irregularity is a hallmark of Rett 
Syndrome, which is attributable to ~26% of sudden death cases in these patients [1]. Several 
brain areas are known to play a role. Signaling from the upper brain may contribute to these 
symptoms as evidenced by the reduction of apneas and impaired breathing during sleep in RTT 
and subsequent reduced activity from the forebrain [60]. Activation of medial prefrontal cortex 
neurons in RTT mouse models improves breathing-related symptoms in heterozygous mice 
[211]. Impaired chemoreceptor sensitivity is another contributor to the RTT-type breathing 
dysfunction. Chemoreceptors in Mecp2-KO mice are unable to detect moderate hypercapnia, and 
when CO2 concentration becomes more severe, the animal begins to hyperventilate to expel the 
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excess CO2 causing periods of hypo and hyperventilation [94]. Exposure to higher CO2 
concentrations stabilizes breathing activity. A recent in-vivo study in our lab has shown that 
brainstem inspiratory neurons are overly active in Mecp2 mutant rats, raising the inspiratory 
drive to phrenic motor neuronal pool and hindering the periodic respiratory bursts of phrenic 
motor neurons [78].  
These impairments are likely to involve multiple neurotransmitter systems including 
monoamine systems. For example, enhancing the amount of NE available in the CNS of RTT 
mice improves respiratory and other symptoms [86, 87, 94]. Restoring the excitation and 
inhibition balance by targeting the glutamate and GABA systems improves RTT symptoms as 
well. The NMDA receptor antagonist and antitussive dextromethorphan has been tested for its 
effectiveness on RTT symptoms in humans. The clinical trial in RTT patients over a six month 
period showed an overall improvement in condition with a decrease in seizure events, increase in 
cognitive function, and improvement in behavioral functioning [236]. CPS also has the 
antitussive effect, although its targets are different from dextromethorphan’s. Our results indicate 
that GIRK channel inhibition with CPS improves respiratory symptoms in Mecp2 mutant mice. 
This finding suggests that agents such as CPS acting on brainstem GIRK channels appear useful 
as therapeutical drugs for treatment of RTT-type breathing disorders [237].  
An early study in human Rett patients has shown that the opioid receptor antagonist 
Naltrexone improves respiratory disturbances and reduces the occurrence of seizures, though 
motor impairment progresses faster [238]. Because opioid receptors are coupled to GIRK 
channels, this previous study supports the use of CPS for RTT. While Naltrexone’s effects are 
specific to opioid receptors, CPS’s effect seems theoretically more widespread, targeting GIRK 
channels that are coupled to other neurotransmitter systems as well. For instance, studies have 
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shown that agonists of the GPCR 5-HT1a improve respiratory symptoms in human RTT patients 
and RTT mice [84, 85, 189]. With dosing optimization and perhaps chronic administration, CPS 
may have an even greater effect. Before moving to clinical trials, the effect of the drug on other 
behaviors should be tested also and it should be tested in female models.  
7.5.4 Locus Coeruleus, GIRK and GABA 
We found that CPS decreases LC excitability, which apparently cannot be a result of 
inhibition of somata GIRK channels in these cells alone, because such a GIRK channel inhibition 
would lead to depolarization increasing excitability of LC neurons. Thus it is possible that the 
inhibitory effect of CPS is mediated by presynaptic mechanisms of enhanced GABA inhibition, 
or pre-presynaptic mechanisms of glutamatergic disfacilitation. Supporting the idea of enhanced 
GABAergic presynaptic inhibition are our results showing that CPS augments GABAergic 
IPSCs, and the inhibitory effect of CPS is completely eliminated in the presence of a GABAA 
receptor antagonist. Instead, the inhibitory effect of CPS is reversed to excitatory. The LC cells 
are known to have GIRK channel expression [239]. Inhibition of the somata GIRK channels 
seems to play a role in the excitatory effect of CPS after presynaptic GABA input is blocked.  
The presynaptic inhibition seems to be produced by GABA release from presynaptic 
terminals rather than enhanced firing activity of GABAergic neurons for two reasons. 1) In the 
presence of phaclofen, a selective GABAB receptor antagonist, CPS fails to augment GABAergic 
IPSCs. 2) The direct effect of CPS on GABAergic neurons in the DTN is inhibitory. Therefore, it 
is possible that CPS acts preferentially on GIRK channels of GABAergic synaptic terminals, 
enhancing GABA release from the terminals and decreasing excitability of the LC cells. Since 
the metabotropic GABAB receptors are coupled to GIRK channels, the target of CPS at the 
synaptic terminals appears to be these GIRK channels. 
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The enhancement of GABA release with CPS treatment is consistent with the 
improvement of symptoms in Mecp2 mutant mice as demonstrated in several previous studies 
[82, 145, 171, 172, 214, 240]. Dysfunction of GABAergic networks, especially within the 
brainstem contribute to the development of breathing irregularities in Mecp2-KO mice. Whole-
brain disruption of the GABA system causes abnormal respiration in RTT, but selective deletion 
of Mecp2 only in GABAergic cells of the hindbrain and not the forebrain recapitulates the 
breathing abnormalities seen in whole-body knockouts [9]. Given that reduced GABAergic 
modulation of LC neurons contributes to the altered properties of these cells [147] and their 
known role in regulating breathing, it is important to study the local circuitry of these neurons. 
Reducing hyperexcitability of LC cells in RTT mice may help reverse dysfunctional NE 
synthesis [10, 193] since increased LC firing activity does not result in greater NEergic 
neuromodulation [205].  
7.5.5 GABAergic Projections to LC 
Our results have shown that the DTN, a highly homogenous group of GABAergic cells, 
has direct axonal projection to the LC, which has not been reported previously. This adds to the 
list of a number of known GABAergic afferents to the LC including the ventrolateral preoptic 
area, the periaqueductal grey, the central amygdala nucleus of the forebrain, the prepossitus 
hypoglossi, the rostral ventrolateral medulla, and recently demonstrated local GABAergic 
neurons in the dmLC nucleus [241-245]. The information of the local circuitry of the 
GABAergic neurons in the brainstem improves our understanding of the LC and its functional 
impairment in Rett Syndrome.  
GABAergic cells in the DTN also known as the dorsal tegmental nucleus of Gudden 
(DTg) project primarily to lateral mammillary neurons [225, 226, 246, 247]. DTN neurons play a 
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role in several behaviors including directional navigation and spatial orientation [248]. 
Subpopulations of the DTN neurons respond differently to changes in angular head velocity and 
head direction [249-251]. With its proximity to the LC, the DTN seems to be positioned as a 
significant contributor of GABA input to LC cells as well.  The DTN neurons also play a role in 
sleep and wakefulness [252, 253], functions that rely primarily on the LC neurons. In the present 
study, we find evidence for functional DTN projections to the LC. Why such a projection has not 
been found in previous studies is unclear. The close locations of LC to DTN may limit 
histological resolution with labeling dye injections to either nucleus. This limitation does not 
seem to exist in optogenetics, as the optostimulation is rather specific for cells that express ChR. 
By optostimulating the DTN nucleus, we have shown that the DTN cells not only project to the 
LC, but also inhibit LC neurons mon-synaptically.  
When optostimulating the DTN we also found that some DTN cells also receive 
GABAergic inputs. We did not try to determine the origin of such a GABAergic input to the 
DTN, as such a study would deviate markedly from the objective of our current studies. We 
speculate that the DTN neurons have recurrent inhibition as a feedback control, as such self-
regulatory mechanism is widely seen in GABAergic neurons [254]. Other potential sources 
include known afferents to the DTN such as the mammillary nucleus, habenular nuclei, the 
prepositus hypoglossus, supragenualis nucleus, septal nuclei, diagonal band of broca, preoptic 
area, and the reticular formation [255-257], some of which contain GABAergic afferents that 
express ChR and may be optostimulated as well [258].  
7.6 Conclusion  
Our results show that the over-the-counter cough medicine CPS improves respiratory 
symptoms of Mecp2 mutant mice. This effect appears to be mediated by blockade of GIRK 
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channels located on GABAergic synaptic terminals. Inhibition of these GIRK channels can 
produce depolarization of the synaptic terminals enhancing GABA release. Given that neuronal 
hyperexcitability is attributed to symptom development in Rett Syndrome, blocking K+ channels 
in GABAergic synaptic terminals seems to be a novel therapeutic approach. Consistently, 
previous literature and the new evidence from our current studies indicate that CPS has an 
overall inhibitory effect in the brainstem supporting further investigation of the use of this drug 








Figure 7.1 Cloperastine inhibited GIRK1-GIRK2 channels heterologically expressed in HEK Cells. 
A. Whole cell voltage clamp was performed in HEK cells expressing GIRK1 and GIRK 2 channels. Inward rectifier 
currents were recorded with a ramp command potential from -100mV to 100mV. B. Individual trace of currents 
obtained from A and displayed in the voltage vs current system. The currents showed clear inward rectification. C. 
Concentration-dependent inhibition of the GIRK1-GIRK2 currents by Cloperastine (CPS). The amplitude of the 






































Figure 7.2 Cloperastine reduced apnea counts and inhibited breathing irregularity in Mecp2 mice. 
A-D. Breathing activity was studied in plethysmography Mecp2 mutant mice before, 30min, 4h and 8h after 
Cloperastine injection. E, G. The number of apneas/ h and breath frequency variation were decreased after 
Cloperastine injection (dark circles, n=13). In comparison to mice with saline injection, significant suppressions of 
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time and treatment on apneas/h, F(3,60) = 4.05, P = 0.01 and significant interaction between time and treatment on f 
variation, F(3,60) = 7.69, P < 0.001; Two-Way Mixed-Model ANOVA; Bonferroni post hoc, Cloperastine treatment 
compared to baseline,* P<0.05, comparison between treatment groups, #, p < 0.05  ##, p < 0.01 ###, p < 0.001).  F, 
H. After data normalization to the baseline levels, the differences in both apnea counts and breath frequency 
variation remained (significant interaction between time and treatment on apneas/h, F(3,60) = 7.11, P < 0.001 and 
significant interaction between time and treatment on f variation, F(1.98,39.54) = 6.91, P < 0.01; Two-Way Mixed-
Model ANOVA; Bonferroni post hoc). I, J. With pooling data from 30 min to 2 h, robust inhibitions of apnea counts 






Figure 7.3 Cloperastine decreased LC excitability by presynaptic mechanisms. 
Whole-cell current clamp was performed in brain slices in vitro. A. LC cells increased their firing activity in 
response to depolarizing current injections (lower panel). B. Evoked firing activity was lower in the presence of 
Cloperastine.  C. The baseline firing frequency of LC cells (open circles, n=12) was compared in the presence of the 
same level of depolarizing command currents with (dark circles) and without 10 μM Cloperastine (open circles). 
Significant reductions in firing activity were seen with CPS. A significant difference of main effect of treatment was 
found, (F(1,11) = 18.58, P < 0.001). A significant interaction was found as well (treatment × current injection 
interaction: F(11,121) = 16.87, P < 0.001; Two-way repeated measures ANOVA). D. In the presence of a GABAA 
blocker, the effect of Cloperastine was reversed to stimulation, which was also statistically significant. A significant 
difference of main effect of treatment was found, (F(1,5) = 24.98, P < 0.01). A significant interaction was found as 
well (treatment × current injection interaction: F(1.71,8.55) = 5.06, P < 0.05; Two-way repeated measures ANOVA). 
Data are shown as means ± SEM. 
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Figure 7.4 Cloperastine Increased spontaneous IPSCs in LC Cells. 
A. Representative recordings of sIPSCs from a WT neuron before and during administration of 10 μM Cloperastine. 
These sIPSC are likely GABAAergic as glycinergic and glutamatergic receptors were blocked. B, D. Comparisons of 
IPSC frequency and amplitude with and without 10 μM CPS. Cloperastine selectively enhanced IPSC frequency 
without any effects on IPSC amplitude (n=23). C, E. Similar results are seen after normalization of IPSC frequency 
and amplitude to baseline levels respectively. (paired Student's t test, *, P<0.05, NS, no significance). 






Figure 7.5 Optogenetic identification of GABAergic input to DTN. 
A. In whole-cell current clamp of DTN neurons in a GAD-ChR mouse, the optostimulating pulses (470 nm light 
with 10 ms duration indicated by the blue bar) were delivered to the same DTN cell through the objective lens 
500ms after the onset of command current injection. The light evoked larger depolarization with firing activity in the 
DTN cell. B. In voltage clamp from another DTN cell, light evoked inward currents that decreased their amplitude 
with depolarization and disappeared at 0mV (likely to be the reversal potential). C1. Schematic showing a brain slice 
with an electrode in the LC nucleus and optostimulation to the DTN. C2, C3. Blue light stimulation (2.0 ms and 5.0 
ms, respectively) to the DTN evoked field potentials in the LC. The shortest latency between onset of light and the 
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Figure 7.6 Cloperastine lowered the excitability of DTN neurons. 
A, B. DTN cells firing activity increased in response to depolarizing current injections. B. DTN cells had lower 
firing frequencies in the presence of Cloperastine. C. Plot of average evoked firing frequency versus current 
injection (F(1,9) = 11.8, P < 0.01; Two-way repeated measures ANOVA; *, P<0.05, **, P<0.01, n=10). D. Firing 
frequencies at peak current injections compared between baseline and 10 μM Cloperastine exposure. (paired 





















































Figure 7.7 DTN cells showed GABAergic IPSCs during and immediately after optostimulation to the same 
nucleus. 
A. Voltage clamp recording of light-induced inward currents in a DTN neuron. IPSC-like outward currents were 
seen immediately after the blue light pulse (horizontal bar 10 ms). Arrows indicate these IPSCs. B. Currents evoked 
by optostimulation from a DTN cell with a holding potential -30 mV. The inward current is likely to be the opto-
current, while the outward current seems to be an average of the IPSCs. C. With prolonged optostimulation, the 
characteristics of IPSCs were revealed: They occurred only during the light exposure and immediately after; the 
IPSCs reversed their polarity becoming inward current with hyperpolarization with the reversal potential between -




Figure 7.8 Bicuculline blocked Cloperastine-induced hypoexcitability of DTN neurons. 
A, B. DTN firing activity was not effected by Cloperastine administration in the presence of bicuculline compared to 
baseline activity. C. Plot of average evoked firing frequency versus current injection showing no significant 
difference between baseline and drug treatment (n=9) (F(1,9) = 0.41; Two-way repeated measures ANOVA; NS, no 





















































Figure 7.9 Cloperastine inhibited GIRK1-GIRK4 channels heterologically expressed in HEK Cells. 

















Figure 7.10 Cloperastine-induced inhibition was blocked by barium. 
A, B. Evoked firing activity of LC cells was similar during bath application of Cloperastine to baseline in the 
presence of 300 μM BaCl2. C. The firing frequency of LC cells was not significantly different during Cloperastine 
administration (n=12) (F(1,11) = 0.149; Two-way repeated measures ANOVA; NS, no significance). D. Evoked firing 
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Figure 7.11 Bicuculline blocked Cloperastine-sensitive IPSCs. 
A. Representative recording of GABAergic sIPSCs with 10 μM Cloperastine and 20 μM bicuculline. B, C, D. 
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Figure 7.12 Cloperastine had no significant effects on IPSC frequency and amplitude in the presence of 
phaclofen. 
A, C. Bar graphs comparing IPSC frequency and amplitudes respectively in LC cells before and during bath 
application of 10 μM Cloperastine (n=10). B, D. Normalized frequency and amplitude data respectively. (paired 
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Figure 7.13 Field potential recordings in contralateral LC and reticular formation. 
A. Field potential recording in LC with optostimulation of the contralateral DTN. Blue bar indicates blue light pulse 



















8 General discussions 
We sought to discover the validity of mouse models of RTT that are more representative 
of the disease in humans compared to widely established models. In addition, we tested the 
effectiveness of a novel treatment method to alleviate breathing abnormalities in RTT mice. We 
found that symptomatic Mecp2+/- mice can objectively be identified using newly established 
criteria and effectively treated for respiratory disturbances. The common occurring Mecp2 gene 
mutation R168X creates behavioral and cellular phenotypes resembling those resulting from a 
complete gene deletion. Our studies further demonstrate that breathing dysfunction and 
alterations of neuronal membrane properties caused by Mecp2 mutations are treatable by the 
over-the-counter cough medicine CPS. CPS seems to alleviate breathing dysfunction by 
increasing GABA release from synaptic terminals due to blockade of GIRK channels, which may 
help to ease neuronal hyperexcitability.  
8.1 Mouse model comparability 
Male mouse models of RTT are overwhelmingly used in studies of RTT, although they 
are unrepresentative of the disease. This calls into question the translatability of results using 
these models to human patients. This practice has persisted despite the obvious flaw of this 
model because of both the advantages male mouse models provide and the difficulty in 
identifying symptomatic female mice. The major disadvantages of the female mouse models are 
difficulties in detecting and assessing RTT-like females due to variable symptom severity. 
We have developed objective methods to quickly and objectively identify RTT-like 
Mecp2+/- mice. Though other studies have also quantified breathing abnormalities similar to what 
we did to assess symptom severity in Mecp2 mutant mice, our method has established criteria to 
identify female Mecp2 mice that are more representative of the human disease [15, 259]. Our 
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results indicate that within the population of Mecp2+/- mice, there are RTT-like mice and WT-
like mice. The finding of RTT-like mice is unsurprising, but the proportion of WT-like mice is 
unexpected. This finding is consistent with reports of individuals with RTT causing MECP2 
mutations who present as unaffected and healthy [260, 261]. This may partially be attributed to 
not only the type of MECP2 mutation these patients have, but also the amount of skewing of X 
inactivation [40]. There is no data on the prevalence of these individuals, but our results suggest 
that this population may be larger than expected. 
X chromosome inactivation is a random process and the expected ratio of mutant 
expressing cells to WT expressing cells in Mecp2+/- mice is 1:1. Consequently, the behavioral 
phenotypes of Mecp2+/- are expected to resemble this ratio. However, the percentage of Mecp2+/- 
mice displaying a detectable phenotype is lower than expected at 15-20%. Some studies offer a 
possible explanation relating to skewed X inactivation. While we have evidence that symptoms 
in Mecp2+/- mice seem to favor WT-like behavioral phenotypes on the cellular level, X 
chromosome expression may favor the WT containing chromosome [35]. 
As the majority of previous findings have been discovered using male RTT mouse 
models, these results need to be validated in females. The comparability of symptom severity 
between RTT-like females and Mecp2-/Y mice, as discovered in our study, suggests that findings 
in male mice are applicable to Mecp2+/- mice. Further validating identification using the 
threshold separation method are the similar results using K-means clustering method. Responses 
of RTT-like female mice to high CO2 concentration treatment were comparable to those of 
Mecp2 null mice as well. Impaired chemosensitivity of Mecp2-/Y mice contributes to their 
breathing irregularities [94]. As in Mecp2-/Y mice, breathing instability in Mecp2+/- mice is 
reduced under hypercapnic conditions indicating that the mechanisms underlying breathing 
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dysfunction are similar in both males and females. We also discovered that membrane alterations 
especially, hyperexcitability of LC cells of symptomatic heterozygous Mecp2 mice were similar, 
indicating that cellular dysfunction is comparable to that found in Mecp2-/Y mice.  These results 
are promising because they suggest that therapeutic options discovered using male mouse models 
may be applicable to female models. 
It remains to be seen how the detection parameters identified correlate with X 
chromosome inactivation patterns, but this may be studied in the future. The advantage of our 
method was to identify specific threshold numbers that can be applied across samples. This work 
not only supported emerging work demonstrating that some female mice begin displaying 
symptoms at an age earlier than six months [102], but also that these symptoms can be detected 
at ages younger than before. One weakness of our study is that we performed a cross-sectional 
study rather than a longitudinal study. Tracking when individual mice develop symptoms and 
how they change over time would provide us with more information. Potential future directions 
of this research include performing a longitudinal study, testing if this method can be validated 
with other genotypes, and testing if the grouping based on the respiratory phenotype correlates 
with other symptoms. 
8.2 MECP2 mutations 
Our results demonstrate that the R168X point mutation and the whole gene deletion of 
Mecp2 cause similar behavioral and cellular phenotypes in affected mice. Behaviorally, we 
showed that both strains of RTT mouse models have increased f variation and apneas/hr and the 
motor function is impaired to the same degree. The intrinsic membrane properties of LC and 
Me5 cells, which contribute to respiratory and motor dysfunctions, respectively, were altered, 
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which contribute to their hyperexcitability and resultant behavioral dysfunctions in both strains 
of mice as well. 
As the behaviors in R168X mice are impaired as in Bird mice, it is reasonable that the 
membrane properties of neurons responsible for these behaviors were also similarly affected. 
Both LC and Me5 neurons were hyperexcitable and membrane properties such as resting 
membrane potential were consistently altered, reflecting their hyperexcitability in both mutant 
strains. The behavioral data though, does contradict expectations of cellular alterations based on 
the molecular differences between both gene mutations. 
The similarities in the studied cellular properties are somewhat unexpected, given that in 
Bird mice, no MeCP2 protein is expressed, whereas in R168X mice, a partially functioning 
MeCP2 protein may be expressed. These results suggest that the truncated Mecp2 and its 
potential binding ability does not affect cellular processes. That calls into question the 
significance of protein binding to DNA. This data does suggest, however, that molecular binding 
is ineffectual without secondary domains such as the transcriptional repressor domain (TRD). 
MeCP2’s ability to recruit its reported 40 binding partners appear to be essential for its cellular 
effects [262]. Though there are potentially cellular processes that are differentially affected such 
as cellular metabolism that are beyond the scope of our study, our data provides a further 
understanding of MeCP2’s impact on neuronal membrane properties.  
8.3 RTT treatment 
We have identified an over the counter medicine that can reduce the occurrence of 
breathing abnormalities in a RTT mouse model. It seems to do so by enhancing inhibitory 
GABA activity by blocking GIRK channels located on synaptic terminals. This study indicates 
that there is an alternative way to enhance inhibition in the central nervous system of RTT mice.  
117 
Previous studies have focused on ways to enhance inhibition in the CNS to treat RTT. 
The drug NNC-711, which is a GABA reuptake blocker, has been used to increase the amount of 
GABA available in the synaptic cleft, which can improve symptoms in RTT mice [82]. GABAA 
receptor allosteric modulators such as benzodiazepines, which enhance the effect of GABA 
bound to GABA receptors, are effective in treating RTT symptoms [171]. We have published 
studies from our lab showing that by activating extrasynaptic GABAA receptors, neuronal 
hyperexcitability is reduced in the CNS leading to symptom alleviation [172, 240, 263, 264]. 
Some other studies have sought to decrease hyperexcitability of neurons in Mecp2 mice by 
blocking excitatory neurotransmission or the downstream effects by blocking glutamate 
receptors [265]. Some of these drugs have unintended side effects, such as somnolence. We 
tested the drug CPS as an alternative method to enhance inhibition in the brainstem while 
avoiding serious side effects. 
Based on the literature, CPS is a GIRK channel inhibitor [221]. Evidence indicates that 
blocking these GIRK channels will lead to increased release of neurotransmitters such as GABA, 
glutamate, NE, and 5-HT, which all may play a role in CPS’s effects. Our data suggest that CPS 
may preferentially target GIRK channels on GABAergic cells. It was also expected that CPS 
would increase the excitability of DTN neurons by blocking somatic GIRK channels, which 
would increase GABA release. Instead, we found that CPS decreased DTN excitability as seen in 
LC cells, which further supports the idea that CPS preferentially targets GIRK channels on 
synaptic terminals. How this happens is unclear. One possible mechanism is that CPS could have 
a higher affinity for the synaptic isoform of GIRK channels. Future studies could test this 
hypothesis by observing CPS’s effects on soma, dendrites, and axon terminals. 
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Another alternative explanation for inhibition caused by CPS is that CPS targets other 
proteins. There are studies indicating that CPS may bind to sigma receptors, histamine receptors, 
and sodium-glucose transporters [233], which may also play a role in the inhibition of the CNS 
by this drug. For example, CPS may activate both histamine 3 receptors and GIRK channels, 
simultaneously counterbalancing each other. If the binding affinity for one protein is greater than 
the other or the proportions of each type are unbalanced, the effect on one protein may 
overwhelm the other. Future studies could test the necessity of GIRK channels for CPS-induced 
respiratory improvement in RTT mice by knocking out GIRK channels in Mecp2 mice, given 
that they are viable, or knocking down mRNA expression of GIRK channels to test if CPS still 
has an inhibitory effect. Also, mice could be pretreated with the selective GIRK channel blocker 
such as tertiapin Q [266] to see if the CPS effect remains.  
The LC nucleus has a significant amount of GIRK channel expression mainly in neurons 
[239]. Therefore, blocking GIRK channels directly on LC cells should stimulate these cells. 
However, we saw the opposite effect of GIRK channel inhibition by CPS. Although the 
inhibition of LC cells by CPS is consistent with CPS’s inhibitory effect on cough, the mechanism 
was unclear. Our results suggest that CPS’s enhancement of GABA transmission overwhelms 
the stimulatory effect of CPS directly on LC cells. The stimulatory effect emerges only after 
blocking GABAA receptors. The inhibition of LC cells in RTT mice may help reduce LC 
excitability and correct the defective NE synthesis seen in these individuals. Previous studies 
have shown that increasing the amount of norepinephrine available in RTT mice can help 
alleviate their respiratory problems as well as other symptoms, which would align with CPS’s 
improvement of respiratory symptoms [87].  
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Although side effects of the drug are rare, they must be taken into consideration. There 
are reports of patients developing dystonia when taking this drug, though this occurred in 
combination with other drugs [267, 268]. It is unclear how or if CPS contributed to developing 
dystonia. A RTT patient taking several medications along with CPS could potentially be at risk 
of developing adverse side effects. Also, one study shows that CPS can inhibit hERG channels, 
which play a role in cardiac functioning, which could exacerbate prolonged QT interval in RTT 
[232, 269]. In addition, future studies include performing a dose-dependent study of CPS, testing 
the drug on female mice, and performing a long term study. Our use of CPS to treat RTT 
symptoms is one of few that have tested its effects on behaviors other than cough. CPS was 
previously shown to be effective in improving bladder function in rats with bladder dysfunction 
caused by cerebral infarction, reversing anxiety and depression-like symptoms in mice exposed 
to diethylstilbestrol prenatally, and reducing amphetamine-induced hyperactivity [221, 222, 




This dissertation attempts to address three specific aims regarding the validity of mouse 
models of RTT, the mechanisms underlying symptoms development, and identifying novel 
treatment options. We have found that Mecp2+/- can objectively be separated into symptomatic 
and asymptomatic groups, with approximately 20% of heterozygous Mecp2+/- being 
symptomatic. The breathing patterns in these mice can be stabilized with treatment of 3% CO2. 
The cellular mechanisms causing respiratory dysfunction, as well as other symptoms such as 
impaired motor function are similar between mice with a complete Mecp2 gene deletion and 
those with partial expression of Mecp2. Hyperexcitability of neurons is a common and likely 
significant factor in both cases. This cellular and breathing dysfunction was proven to be 
treatable by administration of the drug cloperastine. Our evidence suggests that its effects are 
mediated by blocking GIRK channels on terminals of GABAergic cells, enhancing GABA 
release and reducing hyperexcitability. These studies demonstrate that multiple mouse models 
can be used to study the mechanisms causing the development of RTT symptoms and 
cloperastine seems to be a potential therapeutic intervention. Therefore, this dissertation provides 
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